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 Abstract 
Pathological calcification is the abnormal deposition of minerals in soft tissues or the 
premature or excessive calcification of normally mineralizing tissues, and is associated 
with several conditions such as coronary heart disease, craniosynostosis and 
fibrodysplasia ossificans progressiva. Treatments are limited in their ability to prevent 
pathological calcification, thus necessitating the development of alternative therapeutic 
strategies. The work presented in this dissertation involves the use of a newly discovered 
phosphopeptide in testing inhibition of mineralization in vitro and treatment of 
pathological calcification in vivo. The global hypothesis was that phosphorylated apatite-
specific peptide, pVTK (VTKHLNQIpSQpSY), will inhibit mineralization by physico-
chemical and/or cellular pathways involving the TNAP-Enpp1-Ank axis. Further, it was 
hypothesized that pVTK will prevent premature hypermineralization, suture fusion and 
abnormal craniofacial morphology in mouse models of craniosynostosis.  
Phosphorylation of serine residues resulted in increased pVTK binding to carbonated 
apatites, as well as dose-dependent inhibition of osteoblast mineralization. Peptide 
phosphorylation was more important than amino acid sequence order for binding to 
synthetic apatite substrates, whereas regulation of osteoblast culture mineralization was 
determined by both serine phosphorylation and sequence order. pVTK was internalized 
by osteoblasts and following treatment for 10-12 days, downregulation of inhibitors of 
mineralization (Enpp1, osteopontin and Ank) and upregulation of promoters of 
xii 
 
 mineralization (TNAP, Runx2 and bone sialoprotein) was observed. It was further 
demonstrated that mineral inhibition was not due to disruption of collagen matrix 
production or calcium chelation with negatively charged pVTK.  
Several murine models of pathological calcification were evaluated as potential 
candidates to demonstrate peptide-mediated inhibition of calcification. pVTK was 
delivered to prematurely mineralizing anterior-frontal cranial sutures in a BMP-linked 
mouse model of craniosynostosis. Treatment with pVTK caused a partial correction of 
craniofacial defects, but did not inhibit primary osteoblast mineralization in vitro or 
premature suture fusion in vivo. Additionally, pVTK caused a decrease in bone quality, 
indicating negative effects of peptide on bone growth or turnover. 
Further in vitro and in vivo evaluation of the mechanisms underlying pVTK-mediated 
inhibition of mineralization will enable the development of a novel class of peptide-based 
drugs, capable of preventing pathological calcification of tissues and biosprosthetic heart 
valve implants. 
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 Chapter 1 
Introduction  
 
1.1.1 Pathological calcification 
Pathological calcification refers to the deposition of minerals in soft tissues that normally 
do not mineralize, or the premature or excessive calcification of normally mineralizing 
tissues. Pathological calcification is observed in several diseases such as coronary heart 
disease, fibrodysplasia ossificans progressiva (FOP), osteoarthritis and craniosynostosis. 
A brief description of some of these conditions and their current modes of treatment is 
presented below. 
 
1.1.2 Vascular calcification 
Coronary heart disease (CHD) refers to the obstruction of blood vessels usually due to 
deposition of fatty plaques (atherosclerosis) and can cause angina and heart attacks. CHD 
was responsible for approximately 1 in every 6 deaths (406,351 deaths total) in the 
United States in 2007 and it is expected that ~785,000 Americans will have a new 
coronary attack each year  [1]. Coronary artery calcification is a strong predictor of CHD 
and mortality from cardiovascular disease [2]. Other major types of vascular calcification 
(pathological mineralization of vascular tissues such as arteries and heart valves) include 
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 medial arterial calcification and valvular aortic stenosis. Medial calcification of arteries 
(Monckeberg’s sclerosis) is associated with type 2 diabetes and chronic kidney disease 
(CKD). Stiffening of blood vessels (resulting in loss of elastance) increases blood 
pressure and cardiac work, promoting heart failure.  
Treatments to prevent cardiovascular calcification are limited and often have adverse 
effects on bone metabolism. Bisphosphonates (traditionally used to treat osteoporosis) 
can physico-chemically inhibit vascular calcification. However, their use is limited by 
adverse effects on bone health when administered at doses high enough to inhibit 
vascular calcification. Also, bisphosphonates rely on renal clearance for elimination from 
the body and, as a consequence, accumulate in the kidneys of CKD patients. 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors or statins are used to treat 
atherosclerosis by reduction of cholesterol levels and also inhibit vascular calcification. 
In vitro mineralization of human aortic smooth muscle cells can be inhibited by statins 
[3]; however, clinical trials have not clearly demonstrated that statins lower vascular 
calcification.  
 
1.1.3 Fibrodysplasia ossificans progressiva (FOP) 
Heterotopic ossification (HO) refers to ectopic bone formation in extra-skeletal sites and 
soft tissues. One example of HO is the rare genetic disorder fibrodysplasia ossificans 
progressiva (FOP) arising from a mutation in the Activin A receptor type I (ACVR1) 
gene which encodes BMP receptor type 1 [4]. FOP affects ~ 1 in 2 million people and is 
characterized by spontaneous calcification of muscles, tendons, ligaments and joints, as 
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 well as malformations of the toes [5]. An inflammatory component is also critical in the 
formation of ectopic bone [6]. FOP cumulatively progresses with age, and most affected 
patients are immobile and dependent on a wheelchair by the time they reach their 
twenties. There is no treatment currently available for FOP. Surgical removal of HO 
lesions induces new outbreaks of ectopic bone formation and therefore must be avoided. 
Flare-ups of FOP can also occur due to injuries from falls, intramuscular vaccinations, 
injections for routine dental care or influenza. While no cure exists for FOP, clinical 
management of symptoms is achieved using anti-inflammatory agents like NSAIDs and 
corticosteroids, analgesics and short-term use of muscle relaxants [7,8]. 
 
1.1.4 Craniosynostosis 
Craniosynostosis is a condition affecting ~ 1 in 2500 live births, in which premature 
fusion of cranial sutures occurs. These sutures are fibrous structures present between the 
bones of the skull, allowing for deformation and expansion of the skull during childbirth 
and subsequent growth and development. The major cranial sutures are analogous in 
humans and rodents, and include the metopic/frontal, coronal, sagittal and lambdoid 
sutures (Figure 1.1). In humans with normal skull development, the metopic suture fuses 
within the first two years after birth, while the remaining three major sutures fuse later in 
adulthood (thirties). In mice, all sutures remain patent throughout the life span, with the 
exception of the posterior frontal suture, which fuses by 30 – 45 days post-birth [9].  
In patients affected with craniosynostosis, the skull is unable to expand normally due to 
the premature fusion and mineralization of one or more sutures, and can cause 
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 craniofacial deformities, blindness, increased intracranial pressure, abnormal brain 
development and in severe cases, even death [10–12]. The majority of craniosynostosis 
cases occur in an isolated manner, but around 15% are observed in conjunction with 
genetic mutations. Crouzon, Pfeiffer and Apert syndrome patients have mutations in 
fibroblast growth factor (FGF) receptors; transcription factors such as TWIST and MSX2 
are affected in Saetre-Chotzen and Boston type craniosynostosis respectively [10,13–15]. 
While these syndromic conditions are associated with altered signaling arising from 
genetic mutations, the causes and molecular mechanisms leading to suture fusion still 
remain unclear.  
The only way to treat craniosynostosis is via surgical procedures, such as cranial vault 
remodeling, open strip craniectomy and endoscopic strip craniectomy followed by 
postoperative molding helmet use. The specific surgical approach is dependent on patient 
age and clinical diagnosis of the complexity of suture fusion (single vs. multiple sutures 
fused), as well as the risk of future resynostosis necessitating multiple surgeries. 
Hence, there is a strong clinical need to develop alternative treatment strategies to prevent 
pathological calcification seen in cardiovascular disease, FOP and craniosynostosis. In 
order to create novel therapeutics against pathological calcification, it is important to first 
gain a firm understanding of the mechanisms involved in the regulation of physiological 
mineralization.  
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 1.2 Bone mineralization regulation 
Bone mineralization is a complex process and involves the interplay between several 
positive and negative regulators of mineralization. One of the important determinants of 
mineralization is the ratio of inorganic phosphate (Pi) to extracellular inorganic 
pyrophosphate (PPi). PPi is a natural inhibitor of mineralization (at micromolar 
concentrations) and is formed as a by-product of several metabolic reactions. The 
concentration of extracellular PPi is regulated mainly by the action of three molecules: 
tissue non-specific alkaline phosphatase (TNAP), ectonucleotide 
pyrophosphatase/phosphodiesterase 1 (Enpp1) and ankylosis protein (Ank). Enpp1 and 
Ank increase the concentration of extracellular PPi – Enpp1 cleaves ATP to release PPi 
and Ank transports PPi from within the cell to the outside, thereby inhibiting 
mineralization [16,17]. TNAP decreases PPi levels by cleaving PPi to generate Pi thus 
promoting calcification [18,19]. The action of these three molecules maintains the PPi/Pi 
ratio, which has a direct consequence on apatitic mineralization – high PPi/Pi ratios 
inhibit, while low PPi/Pi ratios promote mineralization. Several other transporter and 
extracellular matrix proteins are also involved in the regulation of mineralization. Pit-1, a 
sodium-dependent Pi transporter moves Pi into the cell, which is required to initiate 
mineralization [20–22]. Bone sialoprotein (BSP) and osteopontin (OPN) promote and 
inhibit mineralization respectively [23,24]. Runx2 is a nuclear transcription factor that 
promotes bone formation [25]. The interplay between these different promotor and 
inhibitors molecules also maintains normal bone mineralization and prevents abnormal 
calcification in soft tissues. 
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 The presence of osteochondrogenic markers in pathological mineral deposits and the role 
of these markers in the progression of pathological calcification indicate similarities in 
mechanisms between normal bone mineralization and abnormal calcification of soft 
tissues. Some examples are: transdifferentiation of vascular smooth muscle cells into 
osteochondrogenic phenotypes in response to environmental factors [26], widespread soft 
tissue calcification (of blood vessels, kidneys and joints) in Enpp1 knockout mice [27], 
and aberrant FGF and bone morphogenetic protein (BMP) signaling in craniosynostosis 
patients and mice [13,28]. Hence, a better understanding of physiologic mineralization 
and the effect of anti-calcification drugs on mechanisms of mineralization will provide 
useful information for targeting and treating pathological calcification. 
 
1.3 Inhibition of pathological calcification 
Treatment options for vascular calcification, FOP and craniosynostosis are limited or 
even non-existent. Novel non-invasive therapies can significantly alter clinical treatment 
regimens and improve the standard of care for affected patients. Small molecule drugs 
and engineered cytokines, genes or peptides have the potential to be developed into new 
treatments for pathological calcification.  
 
Cardiovascular calcification 
Sodium thiosulfate (STS) used to treat calcific uremic arteriolopathy (CUA) can attenuate 
the progression of vascular calcification in hemodialysis patients without affecting 
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 vertebral bone density; however the mechanism of action is unclear [29]. Calcium-free 
phosphate binders such as sevelamer manage hyperphosphatemia (high circulating 
phosphorus levels) by reducing phosphate absorption and significantly slowing coronary 
and aortic calcification in dialysis patients [30]. Calcimimetics which reduce serum 
calcium levels (e.g. cinacalcet) have been developed more recently and may be useful in 
slowing the progression of vascular calcification [31]. High-throughput screening of 
chemical libraries has been employed to identify small molecule inhibitors of TNAP – 
these compounds were effective in reducing mineralization of vascular smooth muscle 
cells (VSMCs) isolated from Enpp1 knockouts [32,33]. 
 
Fibrodysplasia ossificans progressiva (FOP) 
Advances in the understanding of mutations underlying FOP have led to the identification 
and testing of a few potential drugs in mouse models. A nuclear retinoic acid receptor Ɣ 
agonist was able to prevent HO in mice with FOP, with minimal side effects and rebound 
effects once treatment was stopped [34]. Several small molecule inhibitors of BMP type I 
receptors that were capable of inhibiting HO in a mouse model of FOP have also been 
developed [35,36]. An engineered version of the BMP-anatgonist Noggin molecule, 
mutein, was able to block HO formation in a BMP4-induced model of FOP [37].  
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 Craniosynostosis 
Tissue engineered sutures have been made from collagen and gelatin seeded with 
autologous fibroblasts and BMP-2, and remained patent when implanted into rabbits [38].  
Organ cultures of calvaria have been useful in studying and understanding suture biology, 
as well as the effect of treatments on suture patency [39]. Delivery of biomolecules such 
as TGFβ3, Noggin and anti-TGFβ2 antibodies has prevented suture fusion and 
postoperative resynostosis in animal models of craniosynostosis [39–41]. 
In our lab, we have used a combinatorial phage display process to identify the peptide 
VTKHLNQISQSY (VTK) which binds with specific affinity to apatite [42]. VTK peptide 
has no acidic amino acids, contrary to known naturally occurring ECM protein domains 
and previously designed apatite-binding peptides, and therefore is unlikely to have been 
identified without phage panning. Phosphorylation of the two serine residues on VTK 
(VTKHLNQI(pS)Q(pS)Y) resulted in a 10-fold increase in binding to apatite. 
Additionally, phosphopeptide pVTK caused dose-dependent inhibition of osteoblast 
mineralization in vitro, and this inhibition was regulated by peptide sequence and charge 
distribution (see Chapter 2). Understanding how the phosphorylated peptide interacts 
with cells to inhibit mineralization could enable the development of novel peptides for 
the treatment of pathological calcification.  
 
1.4 Hypotheses and aims 
There is a clinical need to develop new drug treatments for pathological calcification. The 
work in this dissertation involves the development and testing of a new anti-calcification 
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 peptide, pVTK, by studying mechanisms of mineralization inhibition in vitro and 
delivering peptide to prevent craniosynostosis in vivo. 
 
Global hypothesis: Phosphorylated apatite-specific peptide sequence pVTK will inhibit 
mineralization by physico-chemical and/or cellular pathways involving the TNAP-
Enpp1-Ank axis. pVTK will also prevent premature hypermineralization, suture fusion 
and abnormal craniofacial morphology in mouse models of craniosynostosis. 
 
Hypothesis 1: pVTK inhibits mineralization via alteration of the Enpp1-TNAP-Ank axis 
Aim 1: Identify mechanisms of pVTK-mediated inhibition of mineralization in vitro using 
MC3T3 pre-osteoblasts. Assays were performed at the gene and protein-levels to test the 
effect of peptide treatment on mineralization, collagen deposition, Enpp1 and TNAP 
enzyme activity, and osteogenic differentiation in MC3T3 cells.  The effect of peptide 
administration on mineralization at various stages of osteogenic differentiation, and the 
ability to inhibit progression of mineralization after the initiation of mineralization were 
also investigated.  
 
Hypothesis 2: pVTK inhibits premature mineralization, suture fusion and abnormal 
craniofacial morphology observed in craniosynostosis 
Aim 2: A conditional transgenic mouse model of craniosynostosis was used to test the 
efficacy of peptide in inhibiting suture fusion. Characterization of this craniosynostosis 
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 model was conducted, by analyzing craniofacial bone lengths, as well as bone volume 
and tissue mineral density. Additionally, pVTK peptide was locally delivered to the AF 
suture, and skulls were analyzed for changes in craniofacial morphology, suture fusion 
and bone quality. 
 
1.5 Summary and organization of dissertation 
In Chapter 2, inhibition of mineralization of MC3T3 pre-osteoblast cells by 
phosphorylated peptide is demonstrated, along with effects of charge distribution on 
apatite binding and formation.   Chapter 3 extends the work from Chapter 2, identifying 
in vitro cellular and physico-chemical mechanisms of mineralization inhibition using 
MC3T3 cell cultures (Aim 1). Chapter 4 discusses different murine models of 
pathological calcification that were studied to identify a suitable model with a 
reproducible phenotype to test effects of peptide treatment in vivo. Chapter 5 addresses 
Aim 2, wherein a conditional transgenic mouse model of craniosynostosis was 
characterized and treated with peptide to prevent premature hypermineralization of 
cranial sutures. Chapter 6 summarizes the key findings and discusses future directions for 
the work presented in this dissertation. 
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Figure 1.1: Three dimensional rendering of a mouse skull scanned using micro-computed 
tomography depicting the major cranial sutures: AF - anterior-frontal; PF - posterior-
frontal; Cor – coronal; Sag – sagittal; Lam – lambdoid.  
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 Chapter 2 
Phosphorylation-dependent mineral-type specificity for apatite-binding peptide 
sequences1 
 
2.1 Introduction 
Biomimetic materials used in the repair of traumatic or pathologic bone and tooth defects 
endeavor to guide the regeneration of mineralized tissues by providing molecular cues to 
the damaged tissue.  The inherent complexity of skeletal and dental tissues requires not 
only that biomaterials must elicit specific cellular responses that lead to extracellular 
matrix formation, but that the tissue formed must be both spatially and temporally 
controlled, and mineralizable. In vivo, highly coordinated temporospatial control is 
usually provided by biological molecules and cell-to-cell communication, and therefore 
the incorporation of surface or soluble signals in the design of biomaterials is a logical 
approach to influence tissue development [1,2].  A central tenet of biomimetic material 
design for connective tissues is that replicating key aspects of natural extracellular 
matrices will enable materials to achieve a greater level of control over cell function, and 
allow better integration into host tissues.  
1 Published as Addison WN, Miller SJ, Ramaswamy J, Mansouri A, Kohn DH, McKee MD; Biomaterials 
2010; 31: 9422 - 9430 
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 The choice and design of biologic molecules potentially useful in any given physiologic 
milieu depends on factors that include the chemistry of the implantable material itself, 
and the type of defect in a target tissue.  Current scaffolding/implant materials commonly 
used in orthopedic and dental applications such as metals, calcium-phosphate ceramics 
and polymers each present different surface chemistries, topographies and stiffness, and 
each have their inherent limitations and applications.  Although mineral particles can be 
used directly to fill bone and tooth defects and enhance the osseointegration of implants 
[3], induction of bone formation generally requires additional modification by biologic 
molecules [4].  However, processing and design steps used to fabricate implantable 
materials often can be detrimental to incorporation of organic, biologic molecules into the 
implants, an example being the commonly used high sintering temperatures used in the 
processing of implantable ceramics and composites.  The biomimetic precipitation of 
bone-like mineral (BLM) is an alternative process that occurs at physiologic temperatures 
(37°C) not destructive to any  incorporated biologic components [5].  Biomimetically 
produced BLM in turn can provide a scaffold for the adsorption/incorporation or co-
precipitation of biologic molecules, such that biomolecular functions are retained and 
induction of osteogenesis can occur  [6–8]. 
Modification of implantable surfaces with bioactive peptides is one approach to 
designing biomimetic materials.  However, unlike polymeric materials, the surface of 
hydroxyapatite mineral is not easily modified by surface treatments that form functional 
hydroxyl-, amino, or carboxyl- groups commonly used in implant design, resulting in a 
need for peptide sequences that preferentially adhere to this material surface.   
Furthermore, compared to full-length proteins, relatively smaller bioactive peptides are 
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 cheaper and faster to produce, easier to purify, and do not require processing from animal 
sources.  Traditional design methods use peptide sequences adapted from mineral-
binding proteins such as osteopontin, bone sialoprotein and statherin [9–11].  Mineral-
binding sequences in these proteins are rich in acidic residues (aspartate, glutamate and 
phosphoserines) resulting in a net negative charge that promotes binding to positively 
charged calcium at apatite crystal faces [12,13].  These proteins, and peptides derived 
from them, often lack mineral-type specificity – a notable example being osteopontin 
which binds to and influences the growth of hydroxyapatite [14], calcium oxalate [15] 
and calcite [16].  Design of mineral-type specificity is considered advantageous in the 
design of tissue-specific implantable materials, as these may result in better tissue 
integration and function.  New design methods may also be applicable to the 
development of material-specific peptides to be used as molecular probes/sensors to 
identify mineral phases in pathologic crystal deposits, or even as targeting tags for 
delivery of drugs [17] or tissue-specific molecules. 
Previously, we have used phage display to identify a 12-mer peptide sequence – 
VTKHLNQISQSY (herein called VTK) from a combinatorial library of 109 phages – that 
preferentially adsorbs to bone-like mineral and hydroxyapatite [18].  Phage display 
technology involves expressing a library of peptide sequences on the protein coat of a 
bacteriophage, and then panning for sequences that adhere to a ligand or substrate of 
interest [19].  Phage display has been used to identify peptide sequences that bind to 
proteins, DNA, cells, polymers, and even inorganic materials such as silver and titanium 
[19–22].  One limitation of phage display is the inability to include post-translational 
modifications within the peptides being expressed on the phage protein coat.  Post-
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 translational phosphorylation of serine, threonine and tyrosine residues are particularly 
important in proteins and peptides involved in the regulation of biomineralization [23].  
Phosphorylation of serine residues is common in proteins involved in biomineralization, 
and VTK contains two serine residues that could potentially be phosphorylated.  
Phosphorylation could provide a means to further improve peptide adsorption, modulate 
material specificity and modify cellular responses to the peptides.   
In this study, we determined critical design parameters controlling peptide affinity to 
synthetic and biologically secreted apatites by investigating the effects of 
phosphorylation and amino acid sequence scrambling on peptide-mineral binding, and, in 
a functional assay, on their ability to inhibit osteoblast cell culture mineralization.  We 
have also explored the mechanism of mineral-binding of these peptides by 
RosettaSurface computational simulations for peptide structure prediction at the surface 
of mineral. Collectively, these studies provide insight on the role of peptide charge, 
charge distribution, composition and amino acid sequence in the design of functional 
biomaterials.   
 
2.2 Materials and Methods 
2.2.1 Preparation of biomimetic films and apatite disks 
A 5% (w/v) 85:15 polylactic-co-glycolic acid (PLGA, Alkermes)-chloroform solution 
was cast on 12-mm diameter glass slides and dried overnight.  The PLGA films were 
etched in 0.5M NaOH for 7 min., rinsed in ddH2O, and soaked in modified simulated 
body fluid (141 mM NaCl, 4.0 mM KCl, 0.5 mM MgSO4, 1.0 mM MgCl2, 4.2 mM 
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 NaHCO3, 5.0 mM CaCl2.2H20, and 2.0 mM KH2PO4) at pH 6.8 for 5 days at 37°C [8] to 
enable self-assembly of a carbonated apatite layer onto the PLGA substrate.  The 
modified simulated body fluid was changed daily to maintain supersaturation and 
thermodynamic conditions conducive to heterogeneous nucleation of mineral.   
Hydroxyapatite (HA) disks (10 mm in diameter × 4 mm thick) were pressed from powder 
(Plasma Biotal Ltd.) at 1 metric ton for 1 min. and sintered at 1350 °C for 1 h.  
Carbonated apatite disks were made from 5.6% (CA5) and 10.5% (CA10) carbonated 
apatite powders (a generous gift from Dr. Mary Tecklenburg [Central Michigan 
University]).  Carbonated apatite disks (8–10 mm in diameter × 2–4 mm thick) were 
pressed from powders at 0.5 metric ton for 1 min and sintered at 1350 °C for 1 h (heating 
rate of 10 °C/min).  HA and carbonated disks were sonicated in 10 mM HCl, then in 
ddH2O.  All sintered disks (CA5, CA10, and HA) were autoclaved prior to use.  
Macroscopic dimensions of all disks were measured with calipers.  The morphology, 
composition, crystallinity and surface area of the materials have been characterized using 
scanning electron microscopy, Fourier Transform Infrared Spectroscopy, X-ray 
diffraction, and Brunauer-Emmett Teller (BET) methods, respectively, and were 
previously reported [18]. 
2.2.2 Peptide synthesis 
A peptide sequence – VTKHLNQISQSY (VTK) – with high and preferential affinity to 
apatite-based materials was previously discovered from phage display [18,24].  To 
investigate the role of residue charge, charge distribution and sequence as design 
parameters in controlling peptide affinity to synthetic and biologic apatite, 
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 phosphorylated (VTKHLNQIpSQpSY) and scrambled (IYQSKHTLSNQV; 
IYQpSKHTLpSNQV) variants of the VTK peptide were also studied.  Scrambled 
sequences were obtained using a random number generator.  All peptides were fabricated 
on a Rainin Symphony Synthesizer by Fmoc solid-phase chemistry according to standard 
peptide synthesis procedures and characterized as having >86% purity by high-
performance liquid chromatography (University of Michigan Protein Core).  
Phosphorylations at specific serine residues in the peptide sequence were achieved using 
preformed, protected phosphoserine amino acids.  Peptides were labelled on resin before 
cleavage using 5-(and-6)-carboxyfluorescein succinimidyl ester (Molecular Probes C-
1311) (University of Michigan Protein Core).  The peptides used in this study, and some 
of their properties, are summarized in Table 2.1.  Isoelectric points were calculated using 
Scansite [25] and the Compute pI/Mw tool on the ExPASy proteomics server [26]. 
2.2.3 Synthetic peptide adsorption assay 
For each peptide, an UV absorbance value vs. absorbance wavelength graph was 
generated from 200 to 300 nm (BioRad Smartspec 3000).  UV absorbance maxima for 
VTK was at 225 nm.  From these graphs, the wavelength resulting in the highest UV 
absorbance for each peptide was used to generate standard curves (peptide concentration 
vs. UV absorbance) and estimations of peptide concentrations.  Standard curves 
consisting of the concentrations 0, 1, 5, 10, 25, 50, 75, 100, 250, 500, 750, and 1000 
μg/mL were developed for each peptide tested.  From duplicate readings per 
concentration, the error introduced from the detection technique was ~5%.  A modified 
standard curve consisting of values below 100 μg/mL was used for each peptide to 
calculate the unknown peptide amount that adsorbed onto each material tested.  Amino 
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 acid analysis was performed to verify peptide concentration for standard curves created 
with UV absorbance at 205 nm and 225 nm wavelengths.  Peptides were reconstituted in 
ddH2O and diluted to ~500 μg/mL in 50 mM Trizma buffer, pH 7.5.  BLM films, HA, 
CA5 and CA10 disks, and blank TCPS wells were soaked in ddH2O overnight at 4 °C (n 
= 5-6 per material) in 24-well polystyrene tissue culture dishes.  Prior to introducing 1 
mL of the peptide or buffer solutions for negative controls, plates were allowed to warm 
to room temperature and then the overnight solution was removed.  Plates were agitated 
on a Titer Plate Shaker at ~80 rpm for 3 h at room temperature.  The films and disks were 
rinsed with ddH2O and then soaked in a 10 mM HCl solution for 18 h at room 
temperature on the same shaker.  To determine the amount of peptide adsorbed, aliquots 
of the HCl solution were read on an UV spectrophotometer. 
2.2.4 Cell culture 
MC3T3-E1 (subclone 14) murine calvarial osteoblasts [27] (courtesy of Dr. R. 
Franceschi, University of Michigan, Ann Arbor, MI, USA) were maintained in modified 
α-minimum essential media (Invitrogen) supplemented with 10% FBS (Hyclone) and 1% 
penicillin-streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 5% CO2.  All 
experiments were carried out at a plating density of 50,000 cells/cm2.  Cell differentiation 
and matrix mineralization were initiated 24 h after plating by replacing the medium with 
fresh medium supplemented with 50 μg/ml ascorbic acid (Sigma) and 10 mM β-
glycerophosphate (Sigma).  Medium, with or without peptide (see above), was changed 
every 48 h over a 12-day time period.  
22 
 
 2.2.5 Quantification of mineralization 
After 12 days of culture, mineral was visualized by von Kossa staining using 5% silver 
nitrate solution (Sigma).  For quantification of mineralization by measuring calcium 
deposited within the cell/matrix layer, cultures were decalcified with 0.5 N HCl, and 
calcium in the supernatant was determined spectrophotometrically (absorbance at 595 
nm) from duplicate readings per well using a calcium assay kit (Diagnostic Chemicals).  
2.2.6 Assay for cell proliferation 
Cell proliferation and viability in the presence of peptide was measured using the MTT 
assay [28]. Briefly, cells were incubated with 0.5 μg/μL MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide) (Sigma) in medium for 3 h, solubilized with 
DMSO and absorbance measured at 562 nm. 
2.2.7 Binding of fluorescently labelled peptides to osteoblast culture mineral 
Maximally mineralized day 12 osteoblast cultures were incubated with 150 µM of 
fluorescently-labelled peptide in culture medium for 1 h at room temperature.  After 
washing three times with phosphate-buffered saline, cultures were incubated with 30 µM 
calcein blue (Sigma) for 1 h, dried and visualized a Leica DM IL inverted fluorescent 
microscope (Leica). 
2.2.8 Computational modeling and energy calculations 
All simulations were performed using the RosettaSurface Monte Carlo plus minimization 
structure prediction program [29].  Each execution of the program folds a peptide from a 
fully extended conformation and results in an energy-minimized solution- and adsorbed-
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 state structure.  Large structural ensembles of 105 candidate solution- and adsorbed-state 
conformers were generated from which only the 100 lowest-energy structures, from each 
state, were chosen for further analysis.   Fully extended peptide structures were 
constructed with PyMOL (DeLano Scientific).  Hydroxyapatite crystal surface with P21/b 
space group, lattice parameters of a = 9.42, b =2a, c = 6.88 and γ=120°, and positive Ca2+ 
termination on the {100} crystallographic face was constructed with CrystalMaker 
(CrystalMaker Software Ltd.). The {100} face is a highly stable hydroxyapatite surface 
to which several mineralization-related proteins are known to bind [30,31]. 
2.2.9 Statistics 
Data is presented as mean values ± one standard deviation. ANOVA on RANKS with 
Dunn’s post-hoc comparisons (SigmaStat) were used to determine effect of peptide 
sequence on adsorption to each substrate. Effects of phosphorylation (differences 
between VTK and pVTK; VTK-scram and pVTK-scram) and scrambling (differences 
between VTK and VTK-scram; pVTK and pVTK-scram) were also determined from the 
Dunn’s test. Independent samples t-tests were used to determine differences between 
VTK and pVTK on each material and differences in peptide adsorption between BLM 
and HA.  In vitro quantification of mineralization and proliferation were assessed with 
Student’s t-tests for effects of phosphorylation and scrambling (GraphPad Software). 
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 2.3 Results 
2.3.1 Effect of phosphorylation on peptide adsorption to synthetic apatite-based 
substrates 
Adsorption of VTKHLNQISQSY (VTK) and VTK phosphorylated at Ser-9 and Ser-11 
(pVTK) to four apatite-based minerals and to tissue culture polystyrene (TCPS) was 
measured using a synthetic peptide adsorption assay.  VTK and pVTK did not adsorb to 
TCPS (Figure 2.1), demonstrating specificity for the apatite-based materials.  
Phosphorylation of VTK peptide led to a 10-fold increase in peptide adsorption to BLM 
(p < 0.001).  Significant increases in peptide adsorption to the carbonated disks – CA5 
and CA10 (p < 0.001 for both CA5 and CA10) – were also observed for pVTK relative to 
VTK.  Binding of VTK to HA was not significantly enhanced by phosphorylation.  There 
were no significant differences in the amount of VTK adsorbed to the different apatite 
surfaces.  However, when phosphorylated, VTK adsorption to bone-like mineral was 
significantly greater than to the other apatites.  These data suggest that phosphorylation of 
amino acids on peptide sequences provides a means to control adsorption on carbonated 
apatite surfaces in a material-specific manner, and to increase peptide concentrations on a 
biomaterial surface. 
 
2.3.2 Effect of VTK and pVTK on osteoblast-mediated mineralization 
The MC3T3-E1 osteoblast cell line is a well-established cell culture model widely used 
as an in vitro model of osteogenesis [27,32].  MC3T3-E1 cells secrete and assemble a 
collagenous extracellular matrix that subsequently mineralizes over a 12-day period.  To 
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 examine the effect of VTK and pVTK on osteoblast-mediated mineralization, cultures 
were treated with VTK and pVTK for 12 days and the mineral formed was quantified by 
a biochemical assay for calcium (Figure 2.2A) and was visualized by von Kossa staining 
(Figure 2.2B).  pVTK dose-dependently inhibited mineralization with maximum 
inhibition occurring at concentrations > 200 µM.  VTK had no effect on mineralization at 
comparable doses.  Cell proliferation, as measured by the MTT assay, was reduced 
during days 6 and 9 of culture, but was normal after 12 days of treatment with both 
peptides (Figure 2.2C); thus, the peptides did not appear to be cytotoxic to the 
osteoblasts, and inhibition of mineralization is not attributable to toxicity. 
 
2.3.3 Effects of amino acid sequence scrambling on adsorption to synthetic apatite-
based substrates 
To determine the role of amino acid composition versus amino acid sequence order, and 
therefore the role of net charge versus local charge distribution, scrambled variants of 
VTK and pVTK were synthesized and their adsorption onto apatite-based substrates 
measured.  Scrambling of the peptide sequence does not alter the net charge, but does 
alter the local charge distribution on the peptide, especially in the case of pVTK where 
the two phosphoserine residues are located at the N-terminus at positions 9 and 11.   
Scrambling VTK resulted in a significant increase in adsorption to BLM vs.  HA, 
suggesting increased enhancement of binding specificity towards BLM (Figure 2.3). 
Scrambling of pVTK had no significant effect on binding to BLM nor HA.  Adsorption 
of scrambled pVTK was still greater than VTK or scrambled VTK, although not 
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 statistically significant.  These data suggest that not only are specific residues important 
for binding, but that residue order may be configured to further increase binding affinity.  
Furthermore, the enhanced BLM binding caused by phosphorylation appears to override 
any further impact of a more beneficial charge distribution. 
 
2.3.4 Effect of scrambled pVTK on osteoblast-mediated mineralization 
pVTK-scram inhibited mineralization in osteoblast cultures with significantly less 
potency than pVTK (Figure 2.4). Whereas pVTK exhibited a concentration dependent 
inhibition and at 200 µM completely inhibited mineralization, 200 µM pVTK-scram had 
a significantly lesser effect on mineral inhibition. This suggests that peptide sequence 
order is critical for in vitro regulation of mineralization. 
 
2.3.5 Binding of peptides to mature osteoblast culture mineral 
To determine whether the increased mineralization inhibitory potency of pVTK over 
pVTK-scram also occurred with osteoblast mineral, mature mineralized osteoblast 
cultures were incubated with fluorescently-labelled peptide for 1 h, washed and 
visualized by immunofluorescence microscropy. Mineral was labelled with calcein blue.  
pVTK co-localized with the mineral, indicating strong binding whereas no fluorescence 
was observed for VTK, VTK-scram and pVTK-scram (Figure 2.5).  
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 2.3.6 Computational modelling 
Computational modelling has been beneficial in the understanding of protein/peptide 
interactions with calcium oxalate, calcite and hydroxyapatite crystal surfaces 
[15,29,33,34].  The RosettaSurface protocol in particular is capable of structure 
predictions that are consistent with experimentally measured distances made by solid-
state NMR [29].  To understand the peptide-apatite binding observations made in this 
study, we used molecular modeling to calculate binding energies of  VTK, pVTK, pVTK-
scram and VTK-scram peptides to the {100} face of hydroxyapatite.  The phosphorylated 
peptides pVTK and pVTK-scram had significantly higher (p < 0.001) binding energies 
than the nonphosphorylated peptides (Table 2.2).  Between pVTK and pVTK-scram 
however, there was no significant difference in the binding energies, suggesting that 
scrambling the peptide sequence did not alter binding energies.  VTK and VTK-scram 
also had binding energies that were not significantly different.  Structural prediction 
reveals that for pVTK and pVTK-scram the residues contributing most to the peptide-
crystal surface interaction (shortest mean distance from crystal surface) were the pSer 
residues (Figure 2.6B and D).  Despite VTK and VTK-scram having similar binding 
energies, the residues involved in the binding were different.  For VTK, binding was 
mostly through the basic Lys-3 and the polar residues Gln-10 and Tyr-12, whereas for 
VTK-scram binding occurred via the basic Lys-5 residue (Figure 2.6A and C).  Figure 
2.6E and F show representative structures of VTK and pVTK, respectively.  Lys-3 and 
Tyr-12 on VTK peptide form electrostatic interactions with the crystal surface (Figure 
2.6E).  The phospho-serine residues of pVTK co-ordinate with rows of calcium atoms in 
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 the crystal surface while the side-chain hydroxyl of tyrosine also interacts with the crystal 
surface (Figure 2.6F). 
 
2.4 Discussion 
Phage display provides an alternative design strategy for the identification of material-
specific peptides for use in functional biomaterials.  Using a phage display library 
expressing 109 different peptide sequences, a 12-mer peptide – VTKHLNQISQSY – was 
identified to have specificity toward apatite substrates.  The affinity of a peptide for a 
material surface is determined by the physico-chemical properties of the individual amino 
acids.  We therefore hypothesized that residue order and charge are design parameters 
that could potentially refine peptide affinity and substrate specificity.  Using scrambled 
and phosphorylated variants of VTK, we examined the mechanisms of peptide binding to 
apatite-based biomaterials and the in vitro effects of the peptides on osteoblast-mediated 
mineralization.  The study identifies phosphorylation as a design method to further 
modulate material binding specificity. In summary, our results show that 1) 
phosphorylation increases peptide specificity for bone-like mineral and to a lesser extent 
carbonated apatite, 2) phosphorylation is required for osteoblast mineral binding and 
inhibition, 3) amino acid sequence order and not simply net composition/charge play an 
important role in both apatite-substrate binding and in osteoblast culture mineralization 
inhibition, and 4) binding of peptides to osteoblast culture mineral depends on both 
peptide composition and peptide sequence. 
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 Binding of VTK to apatite may appear somewhat surprising considering that VTK is 
positively charged and lacks any acidic amino acid residues.  In nature, proteins and 
peptides associated with mineral are often (if not typically) acidic and negatively charged 
[12].  Phage display therefore provides a method to identify alternative sequences to 
those identified by protein sequence searching of naturally occurring proteins.  
Hydroxyapatite consists of both cations and anions, so there is the potential for both 
acidic and basic residues to bind to this mineral.  Materials with high surface areas can 
present crystal edges as opposed to crystal faces.  Crystal edges could provide an 
alternative charge distribution compared to crystal faces, further explaining the binding of 
the positive charged peptide to bone-like mineral.  Basic residues are important for 
binding of the salivary protein statherin [35] and human lysozyme to hydroxyapatite [36].  
Indeed, our computational modeling of VTK and VTK-scram binding to hydroxyapatite 
(Figure 2.6) indicated the use of a variety of amino acids including the basic residue 
lysine and polar amino acids such as glutamine and tyrosine. 
Post-translational modification of proteins, for example phosphorylation of serine, 
threonine or tyrosine residues, is an in vivo mechanism to regulate protein function [23].  
We hypothesized that phosphorylation of mineral-binding peptide sequences previously 
identified by phage display would increase not only affinity, but specificity as well.   
Phosphate residues lower the isoelectric point of the molecule thereby increasing its net 
negative charge to favor interaction with calcium within the hydroxyapatite crystal 
lattice.  Phosphorylation of VTK resulted in increased adsorption to bone-like mineral, 
and 5% and 10% carbonated apatite, but not to non-carbonated HA (Figure 2.1).  
Furthermore, the increased affinity of pVTK for BLM was 10-fold higher than that for 
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 CA5 and CA10.  Bone apatite differs from synthetic hydroxyapatite in that some 7% of 
phosphates are substituted by carbonate [37].  Futhermore, carbonate substitutions in 
bone and BLM are mostly Type-B (phosphate group) substitutions, whereas in the 
sintered hydroxyapatites CA5 and CA10, the substitutions are Type-A (for hydroxyl 
groups) [38].  These differences in carbonate composition would presumably alter the 
surface charge distribution thereby influencing peptide affinity.  Increased binding to 
bone-like mineral could also be related to the increased surface area of BLM compared to 
other apatites [18].  Phosphate modifications have implications for the tailored control of 
peptide binding to apatite-based materials, and phosphoserine residues in particular 
appear to be important in peptide interaction with carbonated apatite surfaces.   
Peptide phosphorylation is also a mechanism to control in vitro osteoblast mineralization.  
In this study, we observed that phosphorylation is necessary for inhibition of osteoblast 
culture mineralization (Figure 2.2), presumably through direct binding to crystal surfaces, 
consistent with our cell-free, mineral-binding assays.  Thus, an apatite-specific peptide 
may be tailored to control mineralization in vivo by the incorporation of phosphoserines.  
Inhibition of mineralization has likewise been shown for phosphorylated osteopontin 
peptides in the inhibition of osteoblast mineralization [34], hydroxyapatite [39], calcium 
oxalate [40], and calcite crystal growth [16]. 
Interestingly, we observed that scrambling of pVTK reduced its ability to inhibit 
mineralization (Figure 2.4).  These data indicate that amino acid sequence order and not 
just net charge is important for inhibition of mineralization.  The order of amino acids 
determines any secondary structure the peptide may have which in turn would influence 
its interaction with the mineral surface.  Another explanation could be that although 
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 pVTK and pVTK-scram have equivalent net molecular charges, the phosphoserine 
residues on pVTK are both concentrated at the C-terminus resulting in concentrated 
negative charge at one end of the peptide.  This indicates the charge distribution of a 
peptide is also important for mineral binding and inhibition. In order to achieve inhibition 
of mineralization, the location of the phosphate residues is also a factor to be considered.  
Although scrambling pVTK inhibited mineralization of osteoblast cultures, scrambling 
did not decrease binding to mature osteoblast culture mineral (Figure 2.5).  It is therefore 
possible that inhibition of mineralization and mineral binding are controlled by different 
mechanisms.  It is also possible that different apatite crystal faces are exposed during 
different stages of mineralization and peptides exhibit crystal face specificity in their 
binding. 
The enhanced binding of pVTK (over VTK) to BLM was reflected by the observed 
inhibition of osteoblast culture mineralization by pVTK.  However, scrambling of pVTK 
reduced the inhibitory potency but did not alter BLM binding.  This discrepancy could be 
attributable to morphological or charge differences between biological mineral and BLM, 
and further suggests that different mechanisms are important for binding and for 
inhibition.  This observation could permit the design of a peptide that binds strongly to an 
apatitic substrate but does not prevent osteoblast mineralization. 
As a final note, it is important to note that the peptides did not negatively affect cell 
numbers after 12 days of culture and thus were not cytotoxic.  Lack of toxicity supports 
the potential therapeutic use of peptides such as those examined here.  The mineralization 
inhibitory potential of pVTK could be advantageously used for the management of 
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 ectopic calcifications and hypermineralization pathologies such as kidney stones, 
artherosclerosis and joint ankylosis. 
 
2.5 Conclusions 
Phosphorylation of serine residues on an apatite-binding peptide identified by phage 
display was used to refine peptide specificity for a variety of apatite-based substrates.  
We determined that phosphorylation enhances binding to bone-like mineral and to a 
lesser extent carbonated apatites.  Sequence composition appears to be more important 
than sequence order for binding to synthetic apatite substrates, whereas regulation of 
osteoblast culture mineralization is determined by both sequence composition and 
sequence order. 
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 Peptide Sequence Description Phosphates Net Charge pI 
      
VTK VTKHLNQISQSY Apatite-specific peptide 
identified by phage display 
0 +1 8.6 
pVTK VTKHLNQI(pS)Q(pS)Y Phosphorylated VTK 
 
2 -3 4.8 
VTK-
scram 
IYQSKHTLSNQV Scrambled VTK 
 
0 +1 8.6 
pVTK-
scram 
IYQ(pS)KHTL(pS)NQV Scrambled phosphorylated 
VTK 
2 -3 4.8 
Table 2.1: Amino acid sequences and isoelectric point (pI) of the peptides used in this 
study 
 
 
 
 
 
 
 
 
 
 
35 
 
 Peptide Binding Energy (kcal/mol) 
VTK -4.4 ± 2.8 
pVTK -13.6 ± 5.6 
VTK-scram -4.1 ± 2.2 
pVTK-scram -14.0 ± 3.9 
Table 2.2: Peptide-hydroxyapatite adsorption energies calculated from RosettaSurface 
computational modeling.  Binding energy is the difference between the mean energies of 
the 100 lowest energy adsorbed- and solution-state candidate structures (error given is 
S.D.)  
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Figure 2.1: Adsorption of VTK and phosphorylated VTK  (pVTK) peptides on bone-like 
mineral (BLM), hydroxyapatite (HA), 5.6% carbonated apatite (CA5), 10.5% carbonated 
apatite (CA10) and tissue culture polystyrene (TCPS).  Phosphorylating serine residues in 
VTK peptide increased peptide adsorption onto BLM 10-fold in comparison to non-
phosphorylated VTK.  A similar trend was found on CA5 and CA10 substrates.  Data are 
presented as means ± S.D.  * denotes statistical differences between adsorption of VTK 
vs. pVTK on a given substrate (p < 0.05).  
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Figure 2.2: Mineralizing MC3T3-E1 osteoblast cultures were incubated with VTK and 
pVTK at the indicated concentrations for 12 days followed by mineral quantification by 
(A) calcium content determination expressed as a percentage of untreated control 
cultures, and (B) von Kossa (silver nitrate) staining for mineral. Data are presented as 
means ± S.D. *p < 0.05; ***p < 0.001 from Student’s t-test for statistical differences 
between the two peptides at a given dose. (C) Cell proliferation in osteoblast cultures 
treated with, or without, 200 μm pVTK and VTK as measured by MTT assay. a denotes 
statistical significance between Control and VTK at the given time point. b denotes 
statistical significance between Control and pVTK at the given time point.  
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Figure 2.3: Adsorption of fluorescently-labelled VTK, phosphorylated VTK (pVTK), 
scrambled VTK (VTK-scram) and scrambled phosphorylated VTK (pVTK-scram) on 
bone-like mineral (BLM), hydroxyapatite (HA) and tissue culture polystyrene (TCPS). 
pVTK and pVTK-scram showed significantly higher adsorption to BLM than VTK. All 
peptides except VTK showed significantly higher binding to BLM than HA. Substrate 
specificity of the peptides was confirmed by absence of binding to TCPS. Bracket 
denotes a statistical difference between peptides on BLM (p < 0.05). Data are presented 
as means ± S.D. * denotes statistical differences between adsorption on BLM and HA for 
a given peptide (p < 0.01).  
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Figure 2.4: Effect of scrambling pVTK on inhibition of osteoblast culture mineralization. 
MC3T3-E1 osteoblast cultures were treated with the indicated concentrations of pVTK 
and scrambled pVTK (pVTK-scram) for 12 days followed by (A) quantification of 
mineralization by calcium content determination expressed as a percentage of untreated 
control cultures, and (B) von Kossa (silver nitrate) staining for visualization of mineral. 
Data are presented as means ± S.D. *p < 0.05; **p < 0.01; ***p < 0.001 from Student’s t-
test relative to the untreated control cultures or between the two peptides at a given dose 
(horizontal bars).  
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Figure 2.5: Binding of peptides to osteoblast culture mineral.  Maximally mineralized 
MC3T3-E1 osteoblast cultures were incubated with 150 µM fluorescently tagged 
peptides for 1 h and examined by fluorescence microscopy for peptides (green) and 
calcein blue labelled mineral (blue).  pVTK co-localized with mineral indicating peptide 
binding to hydroxyapatite.  
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Figure 2.6: Molecular modeling of peptide binding to the {100} crystallographic face of 
hydroxyapatite.  Adsorption frequency of individual residues in the 100 lowest-energy 
adsorbed state structures.  Bound residues are defined as residues closer than 5Å for (A) 
VTK, (B) pVTK, (C) VTK-scram and (D) pVTK-scram.  (E) Structural details of a 
representative high-scoring VTK model illustrating  binding of Lys-3,  Gln-10 and Tyr-
12.  (F) Structural details of pVTK binding illustrating binding of Tyr-12,  PSer-9 and 
PSer-11.  (Ca, green; P, orange; O, red; H, white; N, blue).  
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 Chapter 3 
Inhibition of osteoblast mineralization by phosphorylated phage-derived apatite-
specific peptide2 
 
3.1 Introduction 
Biomaterials should be able to communicate with their microenvironment, to encourage 
attachment of specific populations of cells onto their surfaces, and eventually regenerate 
functional tissue. Surface modification of biomaterials with cell-specific biological 
factors can provide the signals required to initiate cell adhesion.  One approach to 
controlling biomaterial surface properties is via functionalization with cell- and material-
specific peptide sequences, which can serve as anchors between a specific cell population 
and a specific material chemistry. Short synthetic peptides (9-30 amino acids in length) 
are advantageous for this application since they can be designed to be non-immunogenic, 
as well as more specific than full length proteins (containing multifunctional domains). 
Further, short peptides are easier and less expensive to synthesize, and are less likely to 
change conformation since they are not as prone to forming secondary/tertiary structures 
[1].  
2 Published as Ramaswamy J, Nam HK, Ramaraju H, Hatch NE, Kohn DH.; Biomaterials 2015; 73: 120 - 
130 
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 Peptide functionalized apatite-based biomaterials are useful in bone tissue engineering as 
they mimic aspects of the organic/inorganic hybrid composition of bone (primarily 
comprised of organic collagen and non-collagenous proteins, and inorganic 
hydroxyapatite). Traditionally, peptide sequences for bone regeneration have been 
derived from known bone-binding motifs found in non-collagenous proteins, often 
containing chains of acidic aspartate and glutamate residues. For example, the peptide 
EEEEEEEPRGDT (E7PRGDT), derived from bone sialoprotein (BSP), consists of a 
poly-glutamic hydroxyapatite binding domain and the ubiquitous RGD cell binding 
domain, and mediates osteoblast attachment to hydroxyapatite and subsequent 
osteogenesis [2,3]. The fusion peptide N15-PGRGDS, comprising a hydroxyapatite 
binding sequence (N15) derived from statherin and the RGD cell binding sequence from 
osteopontin (OPN), facilitates dose-dependent attachment of cells to hydroxyapatite [4]. 
Modular peptides have also been designed that contain apatite binding sequences derived 
from osteocalcin (OCN) and growth factor sequences derived from bone morphogenetic 
protein 2 (BMP2) [5]. These peptides modulate cell binding to apatite, and peptide-coated 
implants stimulate greater bone formation and ingrowth compared to untreated controls 
in a sheep bone-implant gap model [6].    
A novel way of discovering unique material-specific peptides is through the use of phage 
display, which involves panning bacteriophage libraries expressing ~ 109 sequences 
against a material of interest. Using this approach, along with computational modeling 
and ELISA, we identified the apatite-specific 12-mer peptide VTKHLNQISQSY (VTK) 
[7,8]. However, a disadvantage of phage libraries is the inability of bacteriophage to 
incorporate peptide post translational modifications, such as phosphorylation of serine, 
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 threonine and tyrosine residues, which are particularly important in the regulation of 
biomineralization [9,10]. To overcome this drawback and further characterize the 
mineral-binding VTK sequence, we phosphorylated the serine residues on VTK (pVTK) 
and measured a 10-fold increase in adsorption to synthetic biomimetic apatite, and 
significantly higher binding affinity of pVTK compared to non-phosphorylated VTK 
[11].  
Additionally, pVTK caused a dose dependent inhibition of mineralization in MC3T3 pre-
osteoblastic cells, with minimal cytotoxic effects.  Although VTK and pVTK bind to both 
synthetic and cell-secreted mineral, the relative contribution of peptide sequence and 
charge is different between the two forms of apatite.  Phosphorylation and net charge 
were more important in peptide binding to synthetic mineral (scrambling the sequence 
had no effect on binding to biomimetic mineral), whereas peptide sequence and 
phosphorylation/charge were equally important in inhibiting biological mineralization 
(scrambling pVTK resulted in 30% less inhibition compared to  pVTK) [11]. 
Understanding how the phosphorylated peptide interacts with mineral and/or cells to 
inhibit mineralization could enable the application of pVTK in the treatment of 
pathological mineralization. 
Development of therapeutics against pathological calcification is dependent on advancing 
knowledge of mechanisms of mineralization.  Briefly, mineralization is a tightly 
regulated process determined by the concentrations and properties (including net charge, 
charge distribution or number of acidic/phosphorylated amino acid residues) of 
extracellular matrix proteins and other promoter and inhibitor molecules. Inorganic 
extracellular pyrophosphate (PPi) is a natural inhibitor of mineralization (at micromolar 
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 concentrations) and is formed as a by-product of several metabolic reactions. The 
concentration of extracellular PPi is regulated mainly by the action of tissue non-specific 
alkaline phosphatase (TNAP), ectonucleotide pyrophosphatase/ phosphodiesterase 1 
(Enpp1) and the progressive ankylosis protein (Ank). Enpp1 and Ank help inhibit 
calcification by increasing the concentration of extracellular PPi – Enpp1 cleaves ATP to 
release PPi and Ank transports PPi from within to outside the cell [12,13]. TNAP 
decreases PPi levels by cleaving PPi to generate phosphate (Pi), thus promoting 
calcification [14,15]. The actions of TNAP, Enpp1 and Ank maintain the PPi/Pi ratio, 
which has a direct consequence on mineralization – high PPi/Pi ratios inhibit, while low 
PPi/Pi ratios promote mineralization. The presence of Enpp1, Ank, TNAP, as well as 
other osteogenic markers in pathologic mineral deposits [16,17], indicate similarities 
between physiological (bone) and pathological calcification mechanisms, providing new 
opportunities for development of therapeutics against pathological calcification.   
In this study, we hypothesized that pVTK inhibits MC3T3 mineralization via alteration of 
the Enpp1-TNAP-Ank axis. We performed assays at the gene and protein-levels to test 
the effect of peptide treatment on mineralization, collagen deposition, Enpp1 and TNAP 
enzyme activity, and osteogenic differentiation in MC3T3 cells.  The effect of peptide 
administration on mineralization at various stages of osteogenic differentiation, and the 
ability to inhibit progression of mineralization in cultures after the initiation of 
mineralization were also investigated.  
 
50 
 
 3.2 Materials and Methods 
3.2.1 Peptide synthesis 
The following peptides were used: pVTK (VTKHLNQI(pS)Q(pS)Y; pS = 
phosphoserine), FITC-pVTK (FITC-VTKHLNQI(pS)Q(pS)Y) and FITC-E7-RGD 
(FITC-EEEEEEEPRGDT). Peptides were synthesized using Fmoc solid-phase chemistry 
according to standard peptide synthesis procedures and characterized as having >90 % 
purity by high-performance liquid chromatography (University of Michigan Proteomics 
& Peptide Synthesis Core). Phosphorylation at specific serine residues was achieved 
using preformed, protected phosphoserine amino acids. For experiments involving 
fluorescence, peptides were labelled on resin before cleavage using 5-(and-6)-
carboxyfluorescein succinimidyl ester (Molecular Probes C-1311).The peptides were 
dissolved in ddH2O and aliquots were frozen at -20oC until ready to use in experiments.  
3.2.2 Cell culture and overview of experimental design 
MC3T3-E1 (subclone 14) murine calvarial pre-osteoblasts were maintained in alpha 
minimum essential medium supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin (growth medium) at 37oC and 5% CO2 in a humidified incubator. 
For all experiments, cells were seeded at a density of 10,000 cells/cm2 (48 well plates, 
Corning Costar) and allowed to attach overnight in growth medium. Cells were then 
differentiated with osteogenic medium (growth medium supplemented with 10mM β-
glycerophosphate and 50µg/ml ascorbic acid) with or without 300µM pVTK peptide and 
cultured for up to 12 days. Media was replaced every 2 days.  For analysis of calcium, 
media was collected every two days during the media change and frozen at -80oC until 
assayed. 
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 To understand the effect of pVTK on differentiation and mineralization, gene expression 
of Enpp1, TNAP, Runx2, bone sialoprotein, osteocalcin, osteopontin, Ank and Pit-1 was 
measured at days 3, 7, 10 and 12. The expression of collagen I was also measured after 
12 days of peptide treatment.  Protein expression (Runx2, OPN) and enzyme activity 
(Enpp1, TNAP) were also measured to confirm the gene-level data.  To further determine 
the inhibitory effects of the peptide at different stages of osteogenic differentiation and 
mineralization, cells were cultured for 12 days with pVTK added at days 1-6 only 
(corresponding to cell proliferation and matrix production) or days 6-12 only 
(corresponding to matrix maturation and mineralization), and compared to untreated 
controls and cells cultured with the peptide for the entire 12 days.  To assess the effect of 
peptide on mineralizing cell layers, cells were cultured in osteogenic media only until 
mineralization started on day 10, after which pVTK was added and cells were cultured 
until day 14.  
3.2.3 Enpp1 and TNAP enzyme activity assays 
Cell layers were washed with PBS and harvested in a 10mM Tris-HCl, 2mM PMSF, 
0.2% Igepal solution. Samples were frozen at -80oC until assayed, at which time they 
were thawed, homogenized on ice and centrifuged at 12,600 rpm for 10 min at 4oC. 
Supernatants were used to assay for TNAP and Enpp1 activities using substrates p-
nitrophenyl phosphate (Sigma Aldrich) and thymidine 5’ – monophosphate p-nitrophenyl 
ester sodium salt (Sigma Aldrich), respectively, and absorbance was measured at 405nm 
using a microplate reader. A standard curve was used to correlate absorbance units to 
enzyme concentration, and values were normalized to total protein content (obtained 
from BCA assays (Pierce) performed with cell lysate supernatants). 
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 3.2.4 Detection and quantification of mineralization 
von Kossa staining was used to visualize mineralization of cell layers. Briefly, cells were 
fixed in zinc buffered formalin for 30 min and rehydrated using a series of graduated 
ethanol-water mixes. Cells were then exposed to 5% silver nitrate for 30-60 min in bright 
light. Wells were washed, dried and imaged using a Canon dissecting microscope. 
Quantification of the area covered by mineral was performed using ImageJ software 
(NIH). To quantify inorganic calcium levels deposited in cell matrices, cell pellets 
(obtained from cell lysis and centrifugation described above) were demineralized in 0.6N 
HCl overnight and calcium content in the supernatants was determined colorimetrically 
using a Stanbio Total Calcium LiquiColor kit. Calcium content was quantified using a 
standard curve and normalized to total protein content (obtained from BCA assays 
(Pierce) performed with cell lysate supernatants). Calcium content in culture media was 
similarly determined. 
3.2.5 Picrosirius Red collagen staining 
Cell layers were washed with PBS and fixed in Bouin’s fluid for 1h. After washing with 
water, cells were stained with Sirius Red dye for 1h on a shaker. A standard curve was 
created by pipetting known concentrations of calf skin collagen (Sigma Aldrich, 
dissolved in acetic acid) onto microtiter plates, followed by air drying and staining. To 
quantify the collagen content, wells were destained with 0.1N NaOH for 30 min, 
absorbance read at 550nm and the collagen content was determined from the standard 
curve.  
53 
 
 3.2.6 Western Blots 
Cell layers were harvested in lysis buffer containing 150mM NaCl, 50mM TrisCl, 1mM 
EDTA, 1% Triton, 1% sodium deoxycholate, 0.1% SDS and protein inhibitor cocktail 
(Cell Signaling) and frozen at -80oC. Samples were thawed, homogenized on ice and 
centrifuged at 12,600 rpm for 10 min at 4oC, and protein levels were quantified from the 
supernatants using the BCA assay (Pierce). 10ug or 25ug of protein (for osteopontin or 
Runx2 respectively) were mixed with Laemmli loading buffer, boiled and cooled, and 
separated using SDS-PAGE. Proteins were transferred onto PVDF membranes 
(Millipore) and blocked in 5% non-fat milk. Membranes were first probed with primary 
antibodies in 5% non-fat milk or bovine serum albumin and then with horse radish 
peroxidase (HRP)-conjugated secondary antibodies in 5% non-fat milk. Bands were 
visualized by chemiluminescence using SuperSignal West Pico substrate (Thermo 
Scientific). The following primary antibodies and dilutions were used: goat anti-
osteopontin (AF808, R&D Systems) at 1:5000, mouse anti-Runx2 (D130-3, MBL 
International) at 1:500 and rabbit anti-GAPDH (14C10, Cell Signaling Technology) at 
1:1000. The following HRP-conjugated secondary antibodies and dilutions were used: 
anti-goat (A8919, Sigma Aldrich) at 1:20000, anti-mouse (W402B, Promega) at 1:7500 
and anti-rabbit (A0545 Sigma Aldrich) at 1:5000.  
3.2.7 Quantitative Real Time PCR 
Cells were washed with PBS, total RNA was extracted using TRIzol (Invitrogen) and 
cDNA was synthesized using Taqman cDNA synthesis kit (Applied Biosystems). Real 
Time PCR was performed using manufacturer protocols (Applied Biosystems) and 
mRNA levels measured using a standard curve. The following murine genes were 
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 measured using Taqman primer/probes: Enpp1 Enpp1 (Mm01193752_m1), Alpl TNAP 
(Mm00475834_m1), Ibsp BSP (Mm00492555_m1), Bglap OCN (Mm03413826_mH), 
Ank Ank (Mm00445050_m1), Col1a1 Col1 (Mm00801666_g1), Runx2 Runx2 
(Mm00501578_m1), Slc20a1 Pit-1 (Mm00489378_m1) and normalized to the 
housekeeping gene Hprt Hprt1 (Mm01545399_m1). Q-RT-PCR studies were repeated at 
least twice for the majority of genes measured in this study, using different batches of 
cells and mRNA, and PCR was run on different days to confirm reproducibility of the 
findings.  Data is presented as averages of triplicate or quadruplicate samples from one of 
the repeated experiments. Peptide effects are shown as fold changes relative to osteogenic 
treatment without peptide. 
3.2.8 Cell internalization of peptide 
MC3T3 cells were seeded at a density of 15,000 cells/cm2 on tissue culture treated glass 
coverslips in 24 well plates. Peptides were dissolved in ddH2O and diluted to 300µM in 
OPTIMEM (Invitrogen). After media was removed, adherent cells were incubated with 
300µM of FITC-pVTK, FITC-E7-RGD, and OPTIMEM control media (no peptide) for 
1hr. Cells were subsequently washed in PBS, fixed in 10% neutral buffered formalin, and 
mounted on glass slides in Vectashield containing the nuclear stain DAPI (Vector Labs). 
Nikon Ti-Eclipse laser scanning confocal microscope was used to gather images (n=20 
per group, across 4 samples). Each fluorescent channel, DAPI and FITC, was imaged 
individually and merged using Image J.  
3.2.9 Statistics 
Data is represented as mean ± one standard deviation. SigmaPlot was used to perform all 
statistical analyses. Sample sizes of n=3-4 per group were used in all experiments. One 
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 way ANOVA or ANOVA on Ranks with Student Neuman Keuls post hoc multiple 
comparisons tests were used to determine effect of treatment across time (i.e. within 
osteogenic media or osteogenic media containing peptide).  t-tests or Mann Whitney 
Rank Sum tests were used to determine differences between treatments at specific time 
points or calcium concentrations. p < 0.05 denotes statistical significance.  
 
3.3 Results 
3.3.1 Effect of pVTK on mineralization and collagen matrix synthesis 
Treatment of MC3T3 cultures with 300µM pVTK peptide for 12 days caused inhibition 
of mineralization compared to non-peptide treated controls cultured in osteogenic 
medium  (Figure 3.1A). To determine if inhibition of mineralization was caused by 
peptide disruption of collagen matrix deposition, cell layers were stained with PicroSirius 
Red. pVTK treatment did not inhibit collagen production; rather treatment with peptide 
resulted in significantly higher amounts of collagen compared to non-peptide controls 
cultured in osteogenic medium (p = 0.044; Figure 3.1B). Similar trends of increased Col1 
gene expression were seen with peptide treatment compared to osteogenic medium 
controls (Figure 3.1C). 
 
3.3.2 Effect of pVTK on different stages of cell differentiation 
When peptide was added for the first 6 days of culture and then removed, cells were able 
to mineralize (Figure 3.2). When cells were cultured without peptide from days 1-6 and 
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 peptide added only for the last 6 days of culture, mineralization was significantly 
inhibited (p < 0.05). 
 
3.3.3 Effect of pVTK on Enpp1 and TNAP  
Enpp1 enzyme activity and gene expression were significantly inhibited with 12 days of 
peptide treatment (Figure 3.3A, C; p = 0.029 vs. Osteo at both the enzyme and gene-
levels). There was a trend of increased TNAP enzyme activity (Figure 3.3B), while gene 
expression of TNAP was significantly higher with peptide treatment (Figure 3.3D, p < 
0.001 vs. Osteo).  
 
3.3.4 Effect of pVTK on osteogenic gene expression 
Runx2 and BSP levels were also significantly increased with 12 days of peptide 
treatment, whereas OPN, Pit-1 and Ank were significantly decreased compared to 
osteogenic medium controls (Figure 3.4, Osteo + Peptide vs. Osteo for Runx2: p = 0.009, 
BSP: p = 0.004, OPN and Ank: p = 0.029, Pit-1: p = 0.003). There was no significant 
effect of peptide treatment on OCN. 
 
3.3.5 Effect of pVTK on time course of osteogenic expression  
To determine the specific times/stages at which the peptide affected osteogenesis and 
mineralization, gene expression was studied at days 3, 7 and 10 of culture (Figure 3.5). 
Peptide treatment resulted in significantly lower Runx2 expression at day 3 (p = 0.003), 
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 but significantly higher expression at day 10 (p = 0.029 vs. Osteo). There was no 
significant effect of peptide treatment on BSP and TNAP, but a trend of higher 
expression in peptide treated samples on day 10. Significantly lower expression of OPN 
and Pit-1, and a trend of lowered expression of Enpp1 and Ank were observed with 10 
days of peptide treatment (Osteo + Peptide vs. Osteo for OPN: p = 0.002; Pit-1: p = 
0.039). Similar trends were seen in Runx2 and OPN protein expression; peptide treatment 
increased Runx2 expression at day 10 and decreased OPN expression at days 10 and 12 
(Figure 3.6). Overall, expression levels of genes involved in promoting mineralization 
(TNAP, Runx2, BSP, OCN) plateaued or declined by d10, whereas genes that inhibit 
mineralization (Enpp1, Ank, OPN) don’t increase until d7-10. Moreover, this latter set of 
genes do not increase with pVTK.  Peptide treatment resulted in a greater reduction (vs. 
Osteo) in the expression of the inhibitors OPN and Ank compared to the increases in 
expression of the promotors Runx2 and BSP  (vs. Osteo).  
 
3.3.6 Effect of pVTK addition to mineralized cell layers 
From a clinical standpoint, it is important to be able to stop the progress of mineralization 
once it has started. To test if the phosphopeptide was able to stop mineralization after it 
had initiated, cells were cultured in osteogenic medium until they started to mineralize 
(by day 10), and peptide was then added for the remaining culture period until day 14. 
pVTK treatment significantly inhibited the progression of mineralization compared to 
untreated osteogenic media controls at day 12 (Figure 3.7B, ~ 50% lower, p = 0.003 vs. 
Osteo), and also prevented further increases in mineralization from day 12 to day 14 
(Figure 3.7B, Osteo + Peptide: day 12 vs. day 14 not significant; day 14 Osteo vs. day 14 
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 Osteo + Peptide p = 0.006). Enpp1 enzyme activity was also significantly decreased with 
peptide treatment at day 12 (Figure 3.7C, p < 0.001 vs. Osteo), while TNAP enzyme 
activity was significantly higher at day 14 (Figure 3.7D, p = 0.029 vs. Osteo), compared 
to osteogenic media controls. 
 
3.3.7 Cell internalization of peptide 
Both FITC-peptides pVTK and E7-RGD were internalized by MC3T3 cells after 1 hr of 
incubation (Figure 3.8A). However there was more observable translocation of pVTK 
within MC3T3 cells compared to E7-RGD. The FITC-pVTK signal was co-localized 
with the cytoskeletal structure of the cells.  Additionally, vesicular associations 
surrounding many cellular nuclei (Figure 3.8B) were also observed, indicating additional 
intracellular processing of the translocated pVTK peptide. No FITC signal was detected 
in the no-peptide controls. 
 
3.3.8 Effect of pVTK on calcium chelation 
The pVTK peptide has two phosphorylated amino acids and a net negative charge, and 
hence it is possible for the peptide to sequester calcium in solution, preventing 
mineralization. To test if this is a mechanism of pVTK-mediated inhibition of 
mineralization, media was collected at 2 day intervals from cells cultured in the presence 
or absence of peptide and assayed for soluble calcium levels (Figure 3.9A). For untreated 
cells cultured in osteogenic media, calcium levels in the media remained constant over 
time until mineralization started (~ day 10), after which the calcium levels significantly 
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 decreased (Osteo day 10, 12 vs. days 2, 4, 6 and 8, p < 0.001) . In contrast, media calcium 
levels remained constant at all times in peptide treated groups and were significantly 
higher than in untreated osteogenic medium controls on days 10 (p = 0.003) and 12 (p = 
0.047). To determine if mineralization could be achieved by adding supplemental 
calcium, 0.5 or 1mM additional calcium chloride was added to cells with or without the 
peptide, and calcium deposition levels measured from demineralized cell layers (Figure 
3.9B). Supplementing calcium concentrations in the media resulted in increased calcium 
deposition in osteogenic medium controls (Osteo 0 mM vs. Osteo 0.5 mM p = 0.016, 
Osteo 0 mM vs. Osteo 1mM p = 0.003), but mineralization was still inhibited in peptide 
treated groups, suggesting that inhibition of mineralization is not due to sequestration of 
calcium.  
 
3.4 Discussion 
Deposition of minerals in soft tissues or the hypermineralization of bones occurs in a 
number of diseases, yet remains poorly understood. Coronary artery calcification is a 
strong predictor of cardiovascular mortality and coronary heart disease, which was 
responsible for approximately 1 in every 6 deaths in the United States in 2007 [18,19]. 
Craniosynostosis occurs at a frequency of 1 in 2500 live births and, if uncorrected, can 
cause craniofacial defects, retardation of brain development and death. However, despite 
the widespread prevalence and morbidity of these and other diseases resulting from 
pathological calcification, treatment options are often limited to surgery and/or drugs, and 
are characterized by inconsistent results, adverse side effects on other tissues, and a lack 
of clear knowledge on mechanisms. The data reported in this paper demonstrate the 
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 ability of a novel peptide, pVTK, to inhibit cellular mineralization in vitro and a potential 
role for peptides in treating abnormal mineralization conditions in vivo.  
Phosphorylation of serine residues is an important post-translational modification via 
which mineralization is controlled. For example, the acidic and phosphorylated protein 
osteopontin loses its mineral inhibition potential when dephosphorylated [20,21]. 
Similarly, only the phosphorylated form of the VTK peptide (pVTK) inhibits 
mineralization of MC3T3 cells [11].   Mineralization can be disrupted or delayed by 
insufficient or aberrant collagen matrix deposition. However, pVTK treatment 
significantly increased collagen deposition (Figure 3.1B) and Col1 gene expression 
(Figure 3.1C) in MC3T3 cells. Further, in cells treated with peptide at early stages of 
culture (days 1-6 only), matrix mineralization was rescued once normal osteogenic 
culture conditions resumed at later stages of culture (days 7-12) (Figure 3.2), suggesting 
the organic matrix, which serves as a template for mineralization, was not compromised 
by pVTK. Collectively, this data indicates that the inhibition of mineralization does not 
appear to be due to the peptide interfering with collagen deposition. 
Clinically, pathological calcification is detected only after significant sized mineral 
deposits have formed, typically due to presentation of other related symptoms or because 
of limitations in detection resolution. However, once detected, it is important to be able to 
stop further progression of mineralization. To test the potential for inhibiting progression 
of mineralization, peptide was added to MC3T3 cultures that had already started to 
mineralize. pVTK significantly inhibited further mineralization (Figure 3.7B) compared 
to osteogenic medium controls.  This data is crucial to the application of the peptide to 
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 treat pathological calcification by stopping the progression of mineralization after it has 
started. 
The pVTK peptide has two phosphorylated serine residues and consequently a net 
negative charge. These negatively charged groups can chelate positively charged calcium 
ions in solution and prevent mineralization. pVTK treatment resulted in significantly 
higher media calcium levels compared to non-treated controls starting at day 10, when 
the osteogenic controls started to mineralize and deplete the media of Ca (Figure 3.9A). 
However, further supplementation of the medium with CaCl2, which would compensate 
for any ion sequestration, did not result in mineralization (Figure 3.9B), indicating that 
peptide-calcium sequestration is likely not a mechanism of mineralization inhibition.  
The presence of osteochondrogenic markers in pathological mineral deposits and the role 
of these markers in the progression of pathological calcification indicate similarities in 
mechanisms between normal bone mineralization and abnormal calcification of soft 
tissue.  For instance, bovine aortic smooth muscle cells mineralize under calcifying 
conditions, accompanied by loss of smooth muscle specific markers and upregulation of 
osteogenic markers [16]. Enpp1 knockout mice have widespread calcification of the 
coronary artery, aorta, kidneys and joints [17]. Hence, a better understanding of 
physiologic mineralization and the effect of anti-calcification drugs on mechanisms of 
mineralization will provide useful information in targeting and treating pathological 
calcification. In this paper, we studied the effect of pVTK peptide treatment on important 
regulators of osteoblast mineralization. Enpp1 and TNAP directly affect the PPi/Pi 
balance and play critical roles in the regulation of mineralization, along with other 
osteogenic markers, including OPN and BSP.  Peptide treatment inhibited Enpp1 starting 
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 between day 7 and 10 of culture and this inhibition was sustained until the end of culture 
(Figure 3.3, Figure 3.5). The primary role of Enpp1 in osteoblasts is to break down 
nucleoside triphosphates, such as ATP, to generate PPi, a natural inhibitor of 
mineralization [12]. Significant decreases were also seen in the expression of OPN and 
Ank after 10 - 12 days of treatment (Fig. 4, 5). Ank is a membrane transporter protein, 
responsible for transferring PPi from inside the cell to the extracellular environment [13]. 
OPN is a negatively charged and highly phosphorylated non-collagenous protein that 
prevents apatite nucleation and growth [9,22]. Expression of TNAP, Runx2 and BSP was 
significantly higher with pVTK peptide treatment for 10 - 12 days, compared to non-
peptide treated controls cultured in osteogenic medium (Figure 3.3 - Figure 3.5). TNAP 
promotes mineralization by cleaving PPi (or β-glycerophosphate in vitro) to generate Pi 
[14,15], whereas BSP acts as a nucleator of apatite [23]. Runx2 is an osteoblastic 
transcription factor and its overexpression enhances mineralization [24].  
Collectively, our data show that Enpp1, OPN and Ank, which inhibit mineralization 
(directly or indirectly via PPi), were all significantly lowered with pVTK administration, 
whereas TNAP, Runx2 and BSP, which are positive regulators of mineralization, were all 
significantly increased with pVTK treatment. The gene expression data was also 
confirmed at the protein-level (Figure 3.3 and Figure 3.6). Since this scenario of gene and 
protein expression might be expected to increase mineralization, our findings of mineral 
inhibition suggest a possible compensatory mechanism where the peptide treated cells are 
attempting to rescue the reduced mineralization by downregulating the inhibitors and 
simultaneously upregulating the promoters (Figure 3.10).  
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 pVTK peptide was internalized by MC3T3 cells and localized to cytoskeletal and 
vesicular structures (Figure 3.8). However, despite being taken up intracellularly within 
one hour of incubation, no effect of the peptide treatment was observed at early stages of 
culture, and most differences in gene and protein expression between peptide treated cells 
and controls occurred only after mineralization started (around day 10 of culture; Figure 
3.2 - Figure 3.6). Additionally, pVTK binds strongly to both biomimetic synthetic 
mineral and MC3T3 secreted mineral, and computational modeling shows that the 
phosphoserine residues contribute most to apatite binding [11]. Hence, it is possible that 
the peptide inhibits mineralization via a combination of physico-chemical and cellular 
mechanisms, by binding strongly to the initially formed mineral nuclei and preventing 
further crystal growth. In response to this lack of mineralization and also by direct 
interaction with pVTK, the cells could be attempting to alter their gene expression 
towards a more pro-mineralization state (Figure 3.10). Further investigation is necessary 
to characterize peptide-mineral interactions as well as determine specific cellular 
compartments involved in peptide internalization.  
Measurement of intracellular and extracellular concentrations of Pi and PPi will also 
provide a better understanding of the effect of peptide on mineralization. In addition to 
their roles in hydroxyapatite formation, Pi and PPi also act as signaling molecules and 
directly affect osteogenic gene expression. Pi  increases OPN and Pit-1 expression in 
MC3T3 cells [25,26]; PPi increases TNAP, OPN and Ank expression and also has a 
concentration-dependent effect on Enpp1 expression in MC3T3 cells [27].  pVTK caused 
an increase in TNAP and a decrease in Enpp1 and Ank expression (Figure 3.3, Figure 
3.4, Figure 3.5). Based on this expression profile, we would expect to find higher 
64 
 
 concentrations of extracellular Pi and lowered concentration of extracellular PPi, 
indicating a shift towards a pro-mineralization state with pVTK administration. However, 
we also observed lowered expression of Pit-1, a sodium-dependent Pi transporter, which 
indicates potentially lowered intracellular concentrations of Pi. Pi needs to enter the cell 
to promote mineralization and influence changes in osteogenic gene expression 
[25,26,28]. Hence it is possible that lower intracellular Pi levels are also contributing to 
the lack of mineralization seen in response to peptide treatment, despite a gene expression 
profile favoring mineralization.  
 
3.5 Conclusions 
Phage-derived phosphopeptide pVTK was shown to inhibit mineralization and this 
inhibition was not due to disruption of collagen deposition or calcium chelation by 
negatively charged pVTK. The timing of peptide administration was important in 
inhibiting mineralization – pVTK treatment at later stages of differentiation (days 7-12) 
was more important in inhibiting mineralization. Further, this peptide could prevent 
progression of mineralization once it has started. pVTK also decreased the expression of 
Enpp1, Ank, OPN and Pit-1, while upregulating the expression of TNAP, BSP, OCN, 
Col1 and Runx2 in MC3T3 cells after 10 - 12 days of treatment The ability of pVTK to 
inhibit mineralization can potentially be translated into therapeutics against pathological 
calcification seen in cardiovascular disease, osteoarthritis or craniosynostosis, or be used 
to prevent failure of biomaterials due to calcification, such as bioprosthetic heart valves. 
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Figure 3.1: Effect of pVTK on mineralization and collagen deposition. MC3T3 cells were 
cultured for 12 days in osteogenic (Osteo) or osteogenic medium supplemented with 
300µM pVTK peptide (Osteo + Peptide) for 12 days. (A) von Kossa staining showed that 
peptide treatment inhibited mineralization compared to osteogenic medium controls; (B) 
Collagen quantification by PicroSirius Red staining showed that peptide treatment 
resulted in significantly higher collagen deposition compared to osteogenic medium; (C) 
Q-RT-PCR for Collagen (Col1) showed a trend of increased gene expression with peptide 
treatment relative to osteogenic treatment (normalized to Hprt housekeeping gene; * p < 
0.05, t-test).  
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Figure 3.2: Effect of pVTK on different stages of cell culture. MC3T3 cells were cultured 
for 12 days in osteogenic medium (Osteo) or osteogenic medium supplemented with 300 
µM pVTK peptide (Osteo + Peptide). Peptide was added during early stage culture (days 
1-6 only, P1-6d), late stage culture (days 7-12 only, P7-12d) or all 12 days of culture (P1-
12d). von Kossa staining and ImageJ analysis of percent area mineralized showed the 
lack of mineralization in cells treated with pVTK on days 7-12 only and for cells treated 
for all 12 days. Cells treated with peptide only on days 1-6 were still able to mineralize 
once peptide was removed. (* p < 0.05 compared to all other groups, 1 way ANOVA on 
Ranks, Student-Newman-Keuls post hoc test).  
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Figure 3.3: Effect of pVTK on Enpp1 and TNAP. MC3T3 cells were cultured in 
osteogenic medium (Osteo) or osteogenic medium supplemented with 300µM pVTK 
peptide (Osteo + Peptide) for 12 days. (A) Enpp1 enzyme activity was significantly 
inhibited with pVTK treatment compared to osteogenic medium; (B) TNAP enzyme 
activity was unaffected by pVTK treatment compared to osteogenic medium; (C) Q-
RTPCR showed that gene expression of Enpp1 was significantly inhibited with peptide 
treatment relative to osteogenic medium; (D) Q-RTPCR showed that gene expression of 
TNAP was significantly increased with peptide treatment relative to osteogenic medium 
(normalized to Hprt;* p < 0.05, ** p < 0.001, t-test or Mann Whitney Rank Sum test). 
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Figure 3.4: Effect of pVTK on osteogenic differentiation. MC3T3 cells were cultured in 
osteogenic medium (Osteo) or osteogenic medium supplemented with 300µM pVTK 
peptide (Osteo + Peptide) for 12 days. Q-RTPCR was used to measure gene expression of 
(A) Runx2, (B) BSP, (C) OCN, (D) OPN, (E) Ank and (F) Pit-1, all normalized to Hprt.  
Runx2 and BSP expression were significantly higher with pVTK treatment relative to 
osteogenic medium. OPN, Ank and Pit-1 expression was significantly lowered with 
pVTK treatment relative to osteogenic medium (normalized to Hprt housekeeping gene; 
* p < 0.05, t-test or Mann Whitney Rank Sum test). 
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Figure 3.5: Effect of pVTK on time course of gene expression. MC3T3 cells were 
cultured in osteogenic medium (Osteo) or osteogenic medium supplemented with 300µM 
pVTK peptide (Osteo + Peptide) and gene expression of (A) TNAP, (B) Runx2, (C) BSP, 
(D) OCN, (E) Enpp1, (F) Ank, (G) OPN and (H) Pit-1, (all normalized to Hprt) was 
measured at days 3, 7 and 10 of culture via Q-RT-PCR. Peptide treatment resulted in 
significantly higher Runx2 expression at day 10 and a trend of higher expression of 
TNAP and BSP on day 10 relative to osteogenic medium. Significantly lowered 
expression of OPN and Pit-1, and a trend of lowered expression of Enpp1 and Ank were 
observed with 10 days of peptide treatment relative to osteogenic medium. 
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Figure 3.6: Effect of pVTK on Runx2 and OPN protein expression. MC3T3 cells were 
cultured in osteogenic medium (Osteo) or osteogenic medium supplemented with 300µM 
pVTK peptide (Osteo + Peptide) and protein expression of Runx2 and OPN was 
measured at days 10 and 12 of culture via Western Blotting. (A) Runx2 expression was 
increased at day 10 with peptide treatment vs. osteogenic medium; (B) OPN expression 
was decreased at days 10 and 12 with peptide treatment vs. osteogenic medium. 
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Figure 3.7: Effect of pVTK on progression of mineralization. MC3T3 cells were cultured 
for 10 days in osteogenic medium until mineralization started, at which time 300µM 
pVTK peptide was added (indicated by arrow on timeline (A)), and cultured for 4 
additional days.  (B) Calcium levels (quantified from demineralized matrices) and (C) 
Enpp1 enzyme activity were significantly reduced with peptide treatment (D) TNAP 
enzyme activity was significantly higher at day 14 with peptide treatment (* p < 0.05 
Osteo vs. Osteo + Peptide at a specific day, t-test, ** p < 0.001 Osteo vs. Osteo + Peptide 
at a specific day, t-test, ^ p < 0.05 compared to day 10 within Osteo or Osteo + Peptide 
treatment group, ^^ p < 0.001 compared to day 10 within Osteo or Osteo + Peptide 
treatment group, % p < 0.05 compared to day 12 within Osteo or Osteo + Peptide 
treatment group, 1 way ANOVA or 1 way ANOVA on Ranks, Student-Newman-Keuls 
post hoc test). 
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Figure 3.8: Internalization of FITC-tagged pVTK. MC3T3 cells were incubated with or 
without FITC-tagged pVTK and E7-RGD peptides for 1 hour and their nuclei were 
stained with DAPI. Representative images of samples were obtained using scanning 
confocal microscopy and merged using Image J. (A) FITC-pVTK was associated with the 
cytoskeleton; 20X magnification (B) Magnified image of peptide-treated cells showed 
vesicular intracellular association of FITC-pVTK; 40X magnification scale bar 100um. 
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Figure 3.9: Effect of pVTK on media calcium chelation. (A) MC3T3 cells were cultured 
in osteogenic medium (Osteo) or osteogenic medium supplemented with 300µM pVTK 
peptide (Osteo + Peptide) for 12 days and the media was collected during media changes 
every 2 days. Quantification of calcium levels in the media showed pVTK treatment 
resulted in significantly higher calcium levels at days 10 and 12 compared to osteogenic 
medium controls. [* p < 0.05 Osteo vs. Osteo + Peptide at a specific day, t-test , ^ p < 
0.001 days 2, 4, 6, 8 vs. days 10 and 12 for osteo, 1 way ANOVA on Ranks, Student-
Newman-Keuls post hoc test]; (B) MC3T3 cells were cultured in osteogenic medium or 
osteogenic medium supplemented with 300µM pVTK peptide, with or without 0.5 or 
1mM of supplemental CaCl2 for 12 days. Calcium levels (quantified from demineralized 
cell matrices) were significantly increased with increasing supplemental media calcium 
levels in osteogenic controls, but no increase in Ca (no mineralization) was seen in 
peptide treated groups (* p < 0.05 compared to groups indicated by bar, or * p < 0.05 
Osteo vs. Osteo + Peptide at a specific calcium concentration; 1 way ANOVA on Ranks, 
Student-Newman-Keuls post hoc test within Osteo or Osteo + Peptide treatment across 
calcium concentration, t-test between Osteo vs. Osteo + Peptide for a specific calcium 
concentration).  
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Figure 3.10: Schematic summarizing the effect of pVTK on osteoblastic markers. Enpp1, 
OPN and Ank inhibit mineralization (directly or indirectly via PPi) and were significantly 
lowered with pVTK administration (dashed lines), whereas TNAP, Runx2 and BSP are 
positive regulators of mineralization and were significantly increased with pVTK 
treatment (thick arrows). This data, in concert with the apatite-binding ability of the 
peptide and temporal sequence of gene expression, suggest a possible compensatory 
mechanism where the peptide treated cells are attempting to rescue the abnormal 
mineralization phenotype by downregulating the inhibitors and simultaneously 
upregulating the promoters. 
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 Chapter 4  
Evaluation of animal models of pathological calcification 
 
Several mouse models of pathological calcification were tested to identify a suitable 
model to assess efficacy of peptide treatment. A brief discussion of animal models 
currently available to study each condition is provided, followed by specific models that 
were tested. 
 
4.1 Vascular calcification 
Calcification of cardiovascular tissues is seen in coronary heart disease, diabetes and 
chronic kidney disease. Stiffening of blood vessels and heart valves increases blood 
pressure, requires more cardiac work, and increases the potential for heart failure. The 
development of animal models of cardiovascular calcification has advanced our 
understanding of the underlying mechanisms. Mutant mice in which the genes encoding 
for Enpp1 and Ank have been knocked out undergo vessel calcification due to lowered 
extracellular PPi levels [1,2]. Matrix Gla Protein (MGP) knockout mice also possess 
highly calcified arteries and valves and die at the age of 2 months from aortic rupture [3]. 
Mice deficient in osteoprotegerin (OPG) develop mineralized arteries, but to lesser 
extents than MGP knockout mice [4]. It is also possible to induce vessel calcification by 
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 using diets high in fat, cholesterol or calcium/phosphate, or using stimulants such as 
nicotine/vitamin D, adenine, warfarin and calcitriol.  
In a first set of experiments, an Enpp1 knockout mouse model (in collaboration with Dr. 
Nan Hatch, University of Michigan and Dr. Jose Millan, Sanford Burnham Institute) was 
characterized for the presence of a vascular calcification phenotype in vitro and in vivo.  
 
4.1.1 Materials and methods 
4.1.1.1 Animals 
All animal procedures were approved by the University Committee on Use and Care of 
Animals (UCUCA) at the University of Michigan. Enpp1+/- heterozygous mice were bred 
to generate homozygous knockout Enpp1-/- and wild type mice. Genotypes were 
determined using tail or ear biopsy samples.  
4.1.1.2 Isolation of primary vascular smooth muscle cells (VSMCs) 
Primary VSMCs were harvested from the aortas of 6-7 and 11-12 week old Enpp1 
knockouts using enzymatic digestions. CO2 was used to sacrifice the animals and aortas 
were dissected from the thoracic region to diaphragmatic insertion and placed in dishes 
containing sterile HBSS with 1% antibiotic-antimycotic solution. The adventitia was 
gently removed using a cotton swab, the vessels were cut open longitudinally and the 
endothelium and blood clots were gently scraped off using a cotton swab. The vessels 
from 6-8 animals were then cut into 3-5mm pieces and digested with collagenase type II 
for 20 min at 37°C, and then completely digested in collagenase type II/elastase type III 
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 solution for 45 min – 1h at 37°C.  The cells were centrifuged at 1000rpm for 5 min, 
supernatant discarded and cells were plated in a T-25 flask in DMEM supplemented with  
20% FBS and 1% antibiotic-antimycotic. Primary VSMCs were characterized using 
immunocytochemistry for positive staining with mouse anti-human α-smooth muscle 
actin and negative staining with rabbit anti-human von Willebrand factor, an endothelial 
cell marker. 100% of harvested cells stained positively for VSMC-specific markers and 
no endothelial cell contamination was observed (data not shown).  
4.1.1.3 VSMC mineralization 
Primary VSMCs were cultured in DMEM or modified alpha-MEM supplemented with 
20% FBS and 1% antibiotic-antimycotic (growth media) at 37°C in a humidified 
atmosphere containing 5% CO2. A7r5 cells (rat VSMC line) and MOVAS cells (mouse 
VSMC line) were cultured in DMEM and modified alpha-MEM, respectively, 
supplemented with 10% FBS and 1% penicillin/streptomycin (growth media) under the 
same conditions as primary cells. For mineralization assays, cells were seeded in 24-well 
plates at a density of 20,000 - 30,000 cells/cm2 and allowed to attach for 24h. Growth 
media was then supplemented with either 10mM β-glycerophosphate/50µg/ml ascorbic 
acid or 2mM inorganic phosphate (4:1 ratio of Na2HPO4:NaH2PO4) and cells were 
cultured for up to 4 weeks with media changes every other day. To assess mineralization, 
cultures were fixed, stained with 5% silver nitrate solution (von Kossa staining) or 
Alizarin Red and imaged using a dissecting microscope. 
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 4.1.1.4 Histology 
Aortas were harvested from two 23 week old Enpp1 knockout mice and blood was 
flushed from the lumens. Tissues were rinsed with PBS, fixed in 10% neutral buffered 
formalin for 24 hours and transferred to 70% ethanol for storage. 5µm sections were 
stained with von Kossa (counterstained with fast nuclear red) or Alizarin Red to observe 
vessel calcification. 
 
4.1.2 Results 
Aortic calcification has been reported in 3 – 5 month old Enpp1 knockout mice and in 
vascular smooth muscle cells (VSMCs) isolated from these mice [1,2]. Mice with an 
aortic calcification phenotype had a mixed genetic background (C57BL6/Sv 129). The 
mice used in the current experiment had been backcrossed until they were on a pure 
C57BL6 background. No vessel calcification was seen through von Kossa staining 
(Figure 4.1). Only a few scattered spots of positive staining were observed with Alizarin 
red (Figure 4.2).  VSMCs isolated from the aortas of Enpp1 knockouts also did not 
mineralize when cultured in osteogenic medium (not shown). Hence, the Enpp1 knockout 
model was unsuitable as it failed to develop pathological vessel calcification. It was 
hypothesized that this difference in phenotype from published reports arose from 
differences in genetic background – aortic calcification occurs when the mice are 
maintained on a mixed genetic background, but this phenotype is possibly lost or lower in 
severity when mice are bred onto a pure C57BL6 background. Differences in genetic 
background among in-bred mouse strains fed an atherogenic diet cause variations in the 
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 degree and frequency of arterial wall calcification [5]. Genetic background also plays a 
role in skeletal mineralization, and affects bone shape, density, microstructure and 
mechanical properties [6–9]. However, bone phenotype of Enpp1 knockouts bred on a 
C57BL6 background was unchanged compared to knockouts bred on a mixed 
background (unpublished observations Hatch lab, not shown).  Thus, although we are 
aware of the effect of genetic background on phenotype, we did not suspect the 
differences to have an effect on vascular mineralization. 
VSMCs derived from wild type mice or immortalized VSMC cell lines also failed to 
mineralize in osteogenic medium containing β-glycerophosphate as a phosphate source 
(Table 4.1). Some mineralization was observed when Pi was used as a phosphate source 
to mineralize VSMCs (Figure 4.3). For our experiments, we required VSMCs to 
mineralize using β-glycerophosphate as a phosphate source, as we intended to test the 
effect of peptide on tissue non-specific alkaline phosphatase (TNAP) which cleaves β-
glycerophosphate for mineralization (while the use of Pi does not involve TNAP activity 
for mineralization). Hence, the effect of peptide treatment could not be tested using 
Enpp1 knockout cardiovascular calcification experimental models. 
 
4.2 Heterotopic ossification in fibrodysplasia ossificans progressiva  
In a percutaneous induction model of fibrodysplasia ossificans progressiva (FOP), a 
Matrigel carrier mixed with rhBMP4 is injected into the abdominal musculature of mice, 
inducing HO formation within 2 weeks of implantation [10]. A transgenic mouse model 
of BMP4 overexpression (under the neuron-specific enolase promoter) exhibits 
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 progressive HO formation characteristic of FOP, eventually leading to immobilization 
[11]. A transgenic mouse model of FOP has been created, where the mice develop HO in 
their joints due to a mesodermal tissue-specific mutation resulting in constitutively active 
BMP signaling [12].  
For our experiments, an inducible transgenic model of FOP was used (in collaboration 
with Dr. Yuji Mishina, University of Michigan), where mice carrying a mutation in the 
gene encoding BMP receptor 1 developed site-specific HO in their hind limb musculature 
[13]. Affected muscles were characterized by inflammatory cell infiltration and edema. 
Progressive loss of mobility and impaired range of motion were observed in hip, knee 
and ankle joints. HO formation was initiated around the tibia and fibula, eventually 
fusing with the pelvis and femur, rendering hip, knee and ankle joints immobile.  
 
4.2.1 Materials and methods 
4.2.1.1 Animals 
All animal procedures were approved by the University Committee on Use and Care of 
Animals (UCUCA) at the University of Michigan. The development of transgenic mice 
carrying the Cre-inducible mutation ALKQ207D has been described [14]. HO was induced 
in the hind limbs of 9-10 day old transgenic mice by retro-popliteal injections of 
adenovirus expressing Cre (0.3 x 109 or 0.7 x 109 plaque forming units) and cardiotoxin, 
an inflammatory toxin that induces muscle degeneration [13]. 
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 4.2.1.2 Treatment and semi-quantitative analysis of HO formed  
Induced mice were treated with 10µl of PBS or 3mM pVTK peptide in one or both legs, 
or left untreated for 10 days (19-20 days of age). Range of motion (ROM) scoring was 
performed by scruffing mice and scoring the angle between the ankle and tibia on a scale 
of 0-3 (Figure 4.4). A score of 0 indicated an angle of less than 20o (normal) while a 
score of 3 indicated an abnormal angle of greater than 135o, caused by maximum HO 
formation. Mice were then sacrificed by CO2 overdose and radiographed with a Faxitron 
machine (90s exposure, 35kV, 3X magnification). The amount of HO visually observed 
on the X-rays was scored on a scale of 0-3, with 0 indicating no HO formation and 3 
indicating maximum HO formation among all animals compared (Figure 4.4). Legs were 
then dissected out from the hip, fixed in 10% neutral buffered formalin and transferred to 
70% ethanol for storage.  
4.2.1.3 Micro-computed tomography 
Pairs of legs were embedded in 1% agarose, placed in a 34 mm diameter tube and 
scanned using a microCT system (µCT100 Scanco Medical, Bassersdorf, Switzerland). 
Scan settings were: voxel size 18 µm, 70 kVp, 114 µA, 0.5 mm AL filter, and integration 
time 500 ms. Three dimensional rendering of scanned legs were used to visualize ectopic 
HO formation. 
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 4.2.2 Results 
Since the phenotype of FOP progression and severity had been documented [13], the 
animal model was not characterized further. The effect of pVTK delivery on inhibition of 
HO was tested. For the first experiment, induced mice (n=11) received PBS and peptide 
in the left and right legs respectively. Four out of 11 mice did not show any differences in 
their range of motion in either leg (score of 0), and the remaining 7 mice mostly scored 
between 0 and 1 (Table 4.2). Median and total ROM scores were higher in right legs 
compared to left legs. Scoring of the X-ray images also showed higher formation of HO 
in the right legs compared to left legs, with µCT images following the same trend (Figure 
4.5).  
To determine if increased HO formation in right legs was truly an effect of treatment, a 
second experiment was conducted where only left legs were treated with PBS (n=7) or 
peptide (n=8), and right legs left untreated. Similar trends were observed as in the first 
experiment – ROM and X-ray scores were higher in right legs compared to left legs 
(Table 4.3) and µCT images also reflected this trend (Figure 4.6). Four more experiments 
were conducted (data not shown), testing various combinations of treatments/no 
treatment in one or both legs as well as different techniques of adenovirus HO induction 
(total of 6 experiments and 60 mice). In the majority of experiments, higher ROM and X-
ray scores were seen in right legs vs. left legs, irrespective of treatment. Additionally, a 
high variability in HO formation was observed both within and across experiments, 
despite being induced with the same amount of virus at the same time. As a result, this 
mouse model of FOP was considered unsuitable to test effects of peptide treatment. 
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 4.3 Craniosynostosis 
Mouse models serve as excellent systems to understand craniosynostosis in humans, for 
the following reasons: a) analogous sets of cranial sutures are found between humans and 
mice differing only slightly in nomenclature (metopic suture in humans is referred to as 
interfrontal or frontal suture in mice, all other sutures are named similarly), b) fusion of 
only the posterior frontal suture in mice with all other sutures remaining patent provides 
the opportunity to study mechanisms underlying suture patency and fusion within the 
same model, c) mutations found in syndromic craniosynostosis patients can be replicated 
in murine models, providing invaluable information on the effects of gain or loss of 
function of various signaling molecules on craniofacial development. Additionally, the 
calvarial model is attractive for testing the efficacy of peptide treatment in vivo as the 
skull experiences minimal mechanical load (compared to load bearing bones) and does 
not involve inflammatory cell infiltration (seen in some models of vascular calcification 
as well as heterotopic ossification), which could complicate the interpretation of 
treatment effects.  
Mice carrying C342Y and S252W mutations in FGFR2 mimic aspects of Crouzon and 
Apert syndrome respectively, characterized by fusion of the coronal suture and other 
craniofacial abnormalities [15–17]. Mutations in FGFR1 simulate conditions seen in 
Pfeiffer syndrome patients, and mutant mice exhibit fusion of frontal, coronal and sagittal 
sutures [18]. Mutations causing constitutively active BMP signaling in cranial neural 
crest cells result in fusion of the anterior frontal (AF) suture [19]. TNAP knockout 
models of hypophosphatasia develop partially fused coronal sutures by three weeks after 
birth [20].  
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 For our experiments, three different models of craniosynostosis were characterized (2 
Crouzon-FGFR2 mutations and 1 BMP mutation) in collaboration with Dr. Nan Hatch 
and Dr. Yuji Mishina (University of Michigan). Methods and results are presented below 
for Crouzon mice experiments. The BMP animal model data is presented in Chapter 5. 
Dr. Hatch has developed two mouse models of craniosynostosis on different genetic 
backgrounds – BALB/c and C57BL6. Both models carry mutations in FGFR2 and mimic 
the Crouzon syndrome of craniosynostosis, characterized by fusion of the coronal suture, 
bulging wide-set eyes and maxillary hypoplasia in humans [21]. The BALB/c model 
shares features with the less severe and more common form of Crouzon syndrome [16].   
 
4.3.1 Materials and methods 
4.3.1.1 Animals 
All animal procedures were approved by the University Committee on Use and Care of 
Animals (UCUCA) at the University of Michigan. FGFR2-C342Y transgenic mice were 
back-crossed onto BALB/c or C57BL6 genetic backgrounds for at least eight generations 
before breeding for experimental use. Heterozygous transgenic and wild type mice 
genotypes were determined using tail or ear biopsy samples [16].  
4.3.1.2 Ex vivo calvarial organ culture 
1-2 day old mice pups were sacrificed by decapitation and skulls dissected out, cleared of 
soft tissue and trimmed to include only the calvaria. Tissues were rinsed in PBS and 
alpha-MEM before being placed in 12-well dishes. Calvaria were cultured in alpha MEM 
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 supplemented with non-essential amino acids, gentamicin, insulin-transferrin-selenite, 
sodium phosphate and ascorbic acid for up to two weeks (media change every 3 days). 
4.3.1.3 Alizarin Red whole skull staining 
Freshly isolated calvaria or cultured samples were fixed in 100% ethanol and stained with 
10ug/ml Alizarin Red S for 1.5 hours on a shaker. Tissues were rinsed with PBS, stored 
in 70% ethanol and imaged using a dissecting microscope.  
4.3.1.4 Histology 
Fixed calvaria were dehydrated using a series of alcohol and xylene washes and 
embedded in methyl methacrylate. Plastic blockswere trimmed parallel to the sagittal 
suture to within 1-2mm from the sagittal suture and polished with 320 grit paper. 10µm 
sections were prepared using a microtome equipped with a tungsten carbide knife, 
transferred to slides and dried. Mineralization was visualized by staining sections with 
von Kossa (counterstained with toluidine blue).  
 
4.3.2 Results 
µCT scans of 4 and 12 week old BALB/c mice indicated only a few point fusions along 
the coronal sutures. Additionally, suture fusion was not clearly observed in all mice and 
was inconsistent from animal to animal (visual observations, data not shown). 
The C57BL6 model was thought to be more severe – preliminary experiments were 
carried out to characterize the craniosynostosis phenotype. Alizarin Red whole mount 
staining of skulls dissected from one/two day old C57BL6 mice showed coronal sutures 
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 that appeared to be fused or close to fusion. Skulls of the same age were also cultured ex 
vivo for 1-2 weeks and stained to better understand the progression of suture fusion in 
these mice; however from visual observation of stained skulls, no clear change in coronal 
suture fusion was determined (Figure 4.7). Cultured calvarial sections stained with von 
Kossa showed coronal suture bones closer to each other, compared to wild type mice 
(Figure 4.8). From these observations, irreversible suture fusion in the C57BL6 model is 
initiated early, possibly even in-utero, making it difficult to treat. Additionally, we faced 
several challenges with mouse breeding – times between litters were long (up to two 
months), and litter yields were small, resulting in small sample sizes. Hence, these 
models of craniosynostosis were also determined to be unsuitable to study the effects of 
peptide treatment on mineral inhibition. 
 
4.4 Conclusions 
Several models of pathological calcification, spanning 3 different clinical disorders 
(cardiovascular calcification, FOP and craniosynostosis), were evaluated as potential 
candidates to test peptide efficacy in vivo. Altering genetic background changed the 
occurrence of pathological calcification phenotypes. Additionally, while breeding mice 
on mixed genetic backgrounds mimics aspects of disease heterogeneity observed in 
humans, large variations in mouse phenotype severity may be introduced, which can 
muddle the interpretation of treatment effects. Therefore detailed evaluation of the effects 
of altering genetic background on the degree and severity of calcification must be 
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 completed before pursuing more experiments studying efficacies of anti-calcification 
treatments. 
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Figure 4.1: Aortas from 23 week old Enpp1 knockout mice were sectioned and stained 
with von Kossa (counter stained with fast nuclear red) to detect arterial calcification. (A) 
4X magnification, (B) 10X magnification, (C) 20X magnification, (D) 40X 
magnification. No calcification was detected within the vessels.  
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Figure 4.2: Aortas from 23 week old Enpp1 knockout mice were sectioned and stained 
with Alizarin Red to detect arterial calcification. (A) 10X magnification, (B) 20X 
magnification and (C) 40X magnification of top portion of (A). A few sites of positively 
stained calcification were observed, indicated by arrows.  
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Figure 4.3: Mineral formation by vascular smooth muscle cells (VSMCs) cultured with 
2mM Pi for 4 weeks and stained by von Kossa. (A) primary murine VSMCs isolated 
from wild type mice, (B) A7r5 rat VSMC line.  
 
 
 
 
 
 
 
 
 
 
A 
B 
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 Timeline VSMC source Culture conditions Result 
2010 - 2012 
5 week old wild type 
male BALB/c mice 
DMEM, FBS, β-
GP/ascorbic acid for 4 
weeks 
No mineral seen by von 
Kossa staining 
 
8 week old wild type 
male BALB/c mice 
DMEM, FBS, β-
GP/ascorbic acid or Pi 
for 4 weeks 
VSMCs cultured with Pi 
showed some diffuse 
dots, no mineral seen 
with β-GP/ascorbic acid 
group (von Kossa 
staining) 
A7r5 rat VSMC cell 
line 
DMEM, FBS, β-
GP/ascorbic acid or Pi 
for 4 weeks 
VSMCs cultured with Pi 
showed had some 
mineralization, no 
mineral seen with β-
GP/ascorbic acid group 
(von Kossa staining) 
A7r5 rat VSMC cell 
line 
DMEM, FBS, β-
GP/ascorbic 
acid/insulin for 4 
weeks 
No mineral seen 
6-7 week old Enpp1 
knockouts, mixed 
genders 
DMEM, FBS, β-
GP/ascorbic acid for 4 
weeks 
No mineral seen (von 
Kossa) 
11-12 week old Enpp1 
knockouts, mixed 
genders 
Passaged in ascorbate-
free medium; 
mineralization 
experiment with β-
GP/ascorbic acid in 
modified alpha-MEM 
and lot tested FBS for 
upto 4 weeks 
No calcium deposition 
seen (demineralized and 
quantified calcium using 
o-cresolphthalein 
complexone method) 
MOVAS mouse 
VSMC cell line 
β-GP/ascorbic acid in 
modified alpha-MEM 
and lot tested FBS for 
upto 3 weeks 
No mineral seen (von 
Kossa, Alizarin Red or 
calcium quantification) 
Table 4.1: Summary of experiments conducted to test for vascular smooth muscle cell 
(VSMC) calcification in culture. Primary cells and cell lines were tested with several 
different combinations of culture conditions and mineralization detection techniques, but 
failed to mineralize.  
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Figure 4.4: Schematics demonstrating scoring for range of motion (ROM) and X-ray 
analysis of heterotopic ossification (HO). Upper panel – scoring for ROM analysis based 
on angles formed between tibia and ankle (adapted from [13]). A score of 0 indicated an 
angle of less than 20o (normal) while a score of 3 indicated an abnormal angle of greater 
than 135o, caused by excessive heterotopic ossification (HO). Lower panels – 
Radiographs demonstrating scoring scheme for X-ray analysis of HO formed in hind limb 
musculature (indicated by arrows). The amount of HO visually observed on the X-rays 
was scored on a scale of 0-3, with 0 indicating no HO formation and 3 indicating 
maximum HO formation among all animals compared.  
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  Range of Motion (ROM) X-ray 
Treatment Left Right Left Right 
Left leg: PBS, 
right leg: 
peptide 
1 0 0 2 
0 0 1 0 
0 1 1 1 
1 1 0 2 
1 2 0 3 
0 1 2 3 
1 1 2 3 
1 1 0 0 
0 0 0 2 
0 0 1 2 
0 0 0 2 
Median 0 1 0 2 
Total 5 7 7 20 
Table 4.2: Range of motion (ROM) and X-ray scoring of mice induced with HO and 
treated with PBS (left leg) and peptide (right leg). Median and total scores were higher in 
right legs than left legs.  
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Figure 4.5: µCT images of legs dissected from HO-induced mice treated with PBS (left 
leg, L) and peptide (right leg, R). More HO was observed in right legs compared to left, 
and there was high variability in phenotype from mouse to mouse.  
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  Range of Motion (ROM) X-ray 
 L R L R 
Left leg: 
peptide, right 
leg: no 
treatment 
1 2 2 2 
0 2 0 3 
1 2 1 2 
1 2 0 3 
1 3 1 2 
2 1 2 2 
2 3 2 3 
2 3 0 3 
Median 1 2 1 2.5 
Total 10 18 8 20 
Left leg: PBS, 
right leg: no 
treatment 
0 3 1 3 
2 1 2 1 
0 0 0 1 
1 2 3 3 
1 2 0 3 
0 1 0 3 
0 2 0 2 
Median 0 2 0 3 
Total 4 11 6 16 
Table 4.3: Range of motion (ROM) and X-ray scoring of mice induced with HO and 
treated with either PBS or peptide (left leg), leaving the right leg untreated. Median and 
total scores were higher in right legs than left legs. 
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Figure 4.6: µCT images of legs dissected from HO-induced mice treated with PBS (left 
leg, L; right leg, R was untreated). More HO was observed in right legs compared to left, 
and there was high variability in phenotype from mouse to mouse.  
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Figure 4.7: Whole mount Alizarin Red staining of calvaria harvested from 1-2 day old 
(P1-2) C57BL6 Crouzon mice (left panels) and calvaria cultured ex vivo for 1 (middle 
panels) and 2 weeks (right panels). Small black arrows point to the coronal suture which 
remains patent in wild type mice (upper panel) and appears to be fused or close to fusion 
in mutant mice (lower panel).  
 
 
 
 
              P1-2                   1 week (P8-9)          2 weeks (P15-17)  
Mutant 
Wild Type 
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Figure 4.8: Calvaria of ex vivo cultured C57BL6 Crouzon mice were sectioned and 
stained with von Kossa (counterstained with Toluidine blue) to visualize coronal sutures 
(red arrows). Sutures were patent in wild type mice, and close to fusion in mutant mice.  
 
 
 
 
 
 
 
 
 
 
 
 
WT MT 
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 Chapter 5  
In vivo delivery of peptide in a mouse model of craniosynostosis 
 
5.1 Introduction 
Craniosynostosis, a condition affecting ~ 1 in 2500 live births, is caused by premature 
fusion of cranial sutures, leading to craniofacial abnormalities, increased intracranial 
pressure, abnormal brain development and auditory and visual defects [1,2]. Genetically 
altered mouse models are useful in replicating and understanding different aspects of 
craniosynostosis, as well as for testing efficacies of new drug treatments.  In this Chapter, 
the phenotype of a transgenic craniosynostosis mouse model with constitutively active 
bone morphogenetic protein (BMP) receptor type 1 was characterized, and the effects of 
pVTK on inhibiting pathological suture calcification in vivo were tested. Mutant mice 
were reported to have enhanced BMP signaling in nasal and frontal bones (derived from 
cranial neural crest (CNC) cells) and developed premature fusion of the anterior-frontal 
(AF) suture starting 8 days after birth [3]. Mutant mice also had craniofacial 
abnormalities such as shorter snouts, wide-set bulging eyes, and lowered bone volume 
fractions in nasal and frontal bones  [3]. For our experiments, further characterization of 
this craniosynostosis model was conducted, by analyzing craniofacial bone lengths, as 
well as bone volume and tissue mineral density. Additionally, pVTK peptide was locally 
delivered to the AF suture, and skulls were analyzed for changes in craniofacial 
morphology, suture fusion and bone quality. 
107 
 
 5.2 Materials and Methods 
5.2.1 Animals 
All animal procedures were approved by the University Committee on Use and Care of 
Animals (UCUCA) at the University of Michigan. Mice were maintained on a mixed 
genetic background – C57Bl6/J and 129S6. Mice with a mutation in BMP receptor 
Bmpr1a were bred with P0-Cre mice, which express the enzyme Cre-recombinase under 
the control of the CNC-specific P0 promoter. Mutant (MT) mice had constitutively active 
BMP receptors and enhanced BMP signaling in CNC-derived frontal and nasal bones. 
Mice expressing only P0-Cre transgene, but not the Bmpr1a transgene, were designated 
as control mice (CT). Mouse genotypes were determined by performing PCR with tail/ear 
tissues biopsies. The following primers were used: Cre-Gamma 
CGAACATCTTCAGGTTCTGCGG, Cre-Omega GTCGATGCAACGAGTGATGAGG, 
TF41:GTGCTGGTTATTGTGCTGTCTC, TF61:ACGACAGTATCGGCCTCAGGAA 
(TF 41/61 used to check for Bmpr1a transgene). 
5.2.2 Subcutaneous calvarial injections 
To determine the optimal age to treat mice with peptide, a time course experiment was 
conducted to characterize mutant phenotype across different ages. Newborn mice were 
injected with 2µl of PBS over the AF cranial suture once a day starting postnatal day 1 
(P1), or left untreated until they were sacrificed at P7, P10, P13 or P17 of age. Skulls 
were dissected out and cleared of soft tissue. Samples were fixed in 10% neutral buffered 
formalin, transferred to 70% ethanol and scanned via µCT. No negative effects were 
observed due to injections (not shown). Based on observations of phenotype progression, 
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 P10 was chosen as the end-point for all subsequent experiments. At ten days of age, the 
mutant phenotype (suture fusion, craniofacial defects) had progressed sufficiently to be 
measurable, allowing improvement or continued progression of the phenotype to be 
detected post treatment. pVTK peptide was dissolved in sterile PBS at 3mM 
concentration and aliquots frozen at -20oC. P1 mice were subcutaneously injected with 
2µl of peptide, PBS or left untreated until P10, at which time they were sacrificed and 
samples processed as described above. 
5.2.3 Micro-computed Tomography (µCT) 
Skulls were embedded in 1% agarose and placed in a 34 mm diameter tube and scanned 
over the entire length of the skull using a microCT system (µCT100 Scanco Medical, 
Bassersdorf, Switzerland). Scan settings were: voxel size 18 µm, 55 kVp, 109 µA, 0.5 
mm AL filter, and integration time 500 ms. A 140 slice region of interest was defined 
around the AF suture, and used for the quantification of bone volume (BV) and tissue 
mineral density (TMD).  
5.2.4 Digital caliper measurements 
Digital calipers were used to measure cranial morphology. The following lengths and 
widths were measured (Figure 5.1): lengths of nasal bone (N), frontal bone (F) and 
parietal bone (P); width between the eyes, and at the widest part of skull (near the 
lambdoid suture). Ratios of the nasal, frontal and combined nasal + frontal bone lengths 
relative to the parietal bone lengths were calculated.  
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 5.2.5 Categorization of phenotype severity 
Large variability in the severity of the mutant phenotype was observed. To overcome this 
inconsistency, mutants were separated into three categories based on the following 
phenotypes: Category 1/mild - genotypically identified as mutant but phenotype 
resembled controls with normal bone shape and patent sutures, Category 2/medium -   
mutant phenotype clearly observed with shorter triangular shaped snouts, wider skulls 
and fused sutures, and Category 3/severe – mutants with severely undermineralized  and 
fragile skulls which were undetectable in µCT scans  (excluded from all analysis) (Figure 
5.2). Body weight, digital caliper measurements and µCT data are presented from all 
mutants combined, as well as classified by categories 1 and 2. 
5.2.6 Histology 
Fixed skulls were decalcified in 10% EDTA (pH 7.4) for 10-14 days, rinsed with water 
and transferred to 70% ethanol. Samples were dehydrated using a series of ethanol 
mixtures and embedded in paraffin. Serial 5µm coronal sections were taken at 150µm 
intervals along the length of the AF suture, starting anterior to the eyes. Sections were 
stained with hematoxylin/eosin and imaged with an Olympus light microscope.  
5.2.7 Primary osteoblast cell culture 
Cranial pre-osteoblasts were isolated from nasal and frontal bones of 1-3 day old 
transgenic mice using a series of enzymatic digestions, as described [4]. Cells were 
maintained in alpha minimum essential media supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin (growth medium) at 37oC and 5% CO2 in a 
humidified incubator. Cells were seeded at a density of 10,000 cells/cm2 (24 well plates, 
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 Corning Costar) and allowed to attach overnight in growth medium. Cells were then 
differentiated with osteogenic medium (growth medium supplemented with 10mM β-
glycerophosphate and 50µg/ml ascorbic acid) with or without 300µM pVTK peptide and 
cultured for 20 days. Media was replaced every 2 days.   
5.2.8 von Kossa staining 
Cells were fixed in zinc buffered formalin for 30 min and rehydrated using a series of 
graduated ethanol-water mixes. Cells were then exposed to 5% silver nitrate for 30-60 
min in bright light. Wells were washed, dried and imaged. 
5.2.9 Statistics 
Data is presented as mean ± standard deviation. SigmaPlot was used to perform all 
statistical analyses. T-tests or Two way ANOVA with Student Newman Keuls (SNK) 
post hoc comparisons were used to determine the effect of genotype (control vs. mutant) 
and treatment (PBS vs. peptide) on body weight, craniofacial and µCT measurements. If 
data was non-parametric, Mann Whitney Rank Sum tests were used to determine 
significance. * p < 0.05 and ** p < 0.001 denote statistical significance. 
 
5.3 Results 
5.3.1 Effect of pVTK on body weight 
PBS treated mutants had trends of lowered body weights than controls (Figure 5.3A). 
Similarly, peptide treated mutants had significantly lowered body weights than controls 
111 
 
 (p = 0.01). Trends of lowered body weight with peptide treatment were observed in 
categorized mutants (Figure 5.3C, D).  
 
5.3.2 Effect of pVTK on AF suture fusion 
 AF sutures in category 1 mutants (tissue sections at the eye-level) were patent (Figure 
5.4A, B), and sutures in category 2 mutants were fused (Figure 5.4C, D), within both 
PBS and peptide treatment types. Sutures remained patent in control mice, as expected 
(Figure 5.4E, F). 
 
5.3.3 Effect of pVTK on craniofacial morphology 
Length ratios of nasal, frontal and nasal + frontal bones relative to parietal bones were all 
significantly lowered in PBS treated mutant mice compared to controls (Figure 5.5A; p < 
0.001). PBS treated mutants had significantly wider skulls at the eye-level than controls 
(Figure 5.5B; p < 0.001). Peptide treated mutants had significantly lowered length ratios 
compared to controls (Figure 5.5A; N/P peptide p = 0.029 F/P, N+F/P, p < 0.001). 
Peptide treatment reduced skull width at the eye-level compared to PBS treated mutants 
(Figure 5.5B; p = 0.022).  
Within category 1 mutants, trends of higher N/P, lowered F/P, N+F/P and eye width were 
measured following peptide treatment, relative to PBS (Figure 5.6A, B).  Within category 
2 mutants, trends of higher length ratios with peptide treatment were measured (Figure 
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 5.6C). Skull width at the eye-level of category 2 mutants was significantly lowered with 
peptide treatment (Figure 5.6D; p = 0.016). 
 
5.3.4 Effect of pVTK on bone volume and tissue mineral density 
BV was significantly lowered in PBS treated mutants compared to controls (Figure 5.7A; 
PBS p = 0.002). TMD was also significantly lower in PBS treated mutants compared to 
controls (Figure 5.7B; p = 0.001). With peptide treatment, BV was significantly lower in 
mutants compared to controls (Figure 5.7A; p < 0.001).  pVTK peptide also lowered BV 
in mutants compared to PBS treatment (p = 0.046). Peptide treatment resulted in 
significantly decreased TMD in control mice compared to PBS treated controls (Figure 
5.7B; p = 0.021). 
Within category 1 mutants, trends of lowered BV and TMD were measured following 
peptide treatment (Figure 5.8A, B). Within category 2 mutants, significantly lowered BV 
was measured following peptide treatment compared to PBS (Figure 5.8C; p = 0.047). 
Category 2 mutants displayed trends of increased TMD following peptide treatment 
(Figure 5.8D). 
 
5.3.5 Effect of pVTK on primary osteoblast culture 
pVTK treatment did not inhibit primary pre-osteoblast mineralization after three weeks of 
culture. Cells treated with peptide mineralized similar to cells cultured in osteogenic 
medium only (Figure 5.9).  
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 5.4 Discussion 
We used a transgenic mouse model of conditionally enhanced BMP signaling in bones 
derived from CNC cells, leading to synostosis of the AF suture (Figure 5.4) [3]. Large 
variation in phenotype severity was observed qualitatively and quantitatively in this 
mouse model of craniosynostosis. The reason for this variability is unknown; we 
hypothesize that mixed genetic backgrounds or differences in the levels of Cre expression 
in breeder pairs could be contributing to the inconsistencies. While variability in 
phenotype is reflective of the heterogeneity seen in craniosynostosis patients, it becomes 
difficult to detect differences arising from treatment.  
To reduce the variance in the data, mice were categorized into mild, medium and severe 
phenotypes (categories 1-3) based on observations of µCT 3D rendered images (Figure 
5.2). Severely affected mutants (category 3) often did not survive beyond the first few 
days after birth; those that survived the duration of the experiment had small skulls that 
were highly undermineralized, lacked structural integrity, and were therefore excluded 
from analysis. Category 2 mutants had wide-set eyes, shorter triangular snouts and areas 
of undermineralized bones. Additionally, AF sutures in category 2 mutants fused 
prematurely. Category 1 “mutants” were identified as mutants by genotyping, but 
phenotypically resembled control mice. Category 1 mice did not have craniofacial defects 
such as shorter noses, wider skulls or large undermineralized areas in the nasal or 
posterior frontal bones (Figure 5.8).  The AF sutures in Category 1 mutants did not 
undergo premature fusion, but remained patent (Figure 5.4). Hence, these mice had no 
abnormal craniofacial conditions.  
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 Mutant mice exhibited craniofacial abnormalities such as wider set eyes and shorter nasal 
and frontal bones length ratios (Figure 5.5). Peptide treatment corrected the wide set eyes, 
by significantly lowering the skull width at the eye level compared to PBS treated 
mutants (Figure 5.5, Figure 5.6). Further, trends of higher nasal and frontal bone length 
ratios were observed in peptide treated category 2 mutants (Figure 5.6), suggesting 
beneficial effects of peptide treatment on craniofacial morphologies. However, AF 
sutures continued to undergo premature fusion irrespective of peptide treatment (Figure 
5.4), suggesting that higher peptide doses or longer administration periods may be 
necessary to prevent suture fusion. Alternatively, the underlying mechanisms 
contributing to craniofacial abnormalities may be distinct from those involved in suture 
fusion in this model of craniosynostosis.  
Mutant mice had significantly lowered BV and TMD around the AF suture, compared to 
control mice (Figure 5.7). pVTK treatment further lowered BV in mutants, and also 
lowered TMD in control mice, compared to PBS treatment (Figure 5.7). Hence it is 
possible that pVTK has negative effects on bone mineralization. Studying bone growth 
and turnover using fluorochrome injections and histomorphometric analysis will provide 
more clarity on the effects of peptide on mineralization in vivo. 
pVTK peptide inhibits the mineralization of MC3T3 pre-osteoblasts [5]. However, no 
inhibition of mineralization was observed with peptide treated primary pre-osteoblasts 
that were isolated from mutant mice (Figure 5.9). We hypothesize that this lack of 
inhibition arises from differences in cytokine signaling in mutant cells compared to 
MC3T3 cells. Pre-osteoblasts isolated from mutant mice exhibit enhanced Smad-
dependent BMP signaling and FGF signaling pathways (and unaltered proliferation, 
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 differentiation or mineralization profiles compared to cells from control skulls) [3]. While 
we have demonstrated altered expression levels of various promotors and inhibitors of 
mineralization in peptide-treated MC3T3 cells [6], we did not examine the effect of 
pVTK on BMP or FGF signaling pathways. Further evaluation of peptide effects on these 
cytokine signaling pathways, as well as their interactions with different regulators of 
mineralization, will help understand better the mechanisms behind pVTK-mediated 
inhibition of mineralization. It is also possible that the scenario of increased BMP 
signaling overrides the effects of pVTK, or that higher peptide concentrations or more 
sustained delivery profiles are required to inhibit mineralization. 
pVTK treatment in a BMP-linked craniosynostosis model had positive effects on some 
aspects of craniofacial morphology, no effect on suture fusion and negative effects on BV 
and TMD. Further reduction in variance of the phenotype severity may provide more 
definitive outcomes following peptide treatment. Evaluation of BMP signaling to confirm 
constitutively active BMP type 1 receptors and enhanced downstream signaling in 
category 1 mice, may provide further insight into understanding the discrepancies 
between genotype and phenotype seen in these mice. Despite the categorization of mice 
based on severities, high variability in the µCT data within category 2 was still observed 
(Figure 5.8), potentially contributing to the lack of statistically significant differences (in 
TMD) observed between treatments. Further sub-categorization within category 2 based 
on BV or body weight measurements, combined with appropriate increases in sample 
size within sub-categories may help to further reduce the inconsistencies and observe 
clear effects of peptide treatment. Measurement of Cre expression levels will also 
identify if variation among breeder pairs is contributing to the high variance in severity. 
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 5.5 Conclusions 
Peptide treatment resulted in a partial correction of craniofacial morphology defects, in a 
mouse model of BMP-linked craniosynostosis. pVTK did not prevent fusion of the AF 
suture and did not inhibit primary mutant-derived pre-osteoblast mineralization in 
culture. Additionally, treatment with peptide lowered bone volume and tissue mineral 
density, indicating negative effects on bone growth and turnover. Studies exploring the 
effects of peptide treatment on BMP and FGF cytokine signaling pathways will provide 
invaluable insight into the mechanisms of peptide-mediated inhibition of mineralization. 
 
Acknowledgements 
I am deeply grateful to Dr. Yuji Mishina (YM) for providing the animal model as well as 
for his guidance and assistance with facilitating all aspects of experiments conducted in 
this chapter. I also thank Haichun Pan for her help with genotyping and Satoru Hayano 
for training me on subcutaneous calvarial injection techniques. Thank you to Michelle 
Lynch and Chris Strayhorn, for their assistance with µCT (School of Dentistry µCT 
Core) and histology (School of Dentistry Histology Core) respectively. This work was 
funded by: NIH/NCRR S10RR026475-01 (µCT), NIDCR/NIH R01DE020843 (YM), 
NIH DE 013380 and DE 015411. 
 
 
 
117 
 
  
Figure 5.1: Schematic depicting locations on mouse skull where craniofacial 
measurements were acquired using digital calipers. Lengths of nasal (N), frontal (F) and 
parietal (P) bones were measured, indicated by distanced between solid red lines. Skull 
width was measured at the eye-level and at the widest point of the skull (near lambdoid 
suture), indicated by dotted lines.  
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Figure 5.2: Categorization of P10 mutants based on phenotype severity as observed in 
µCT 3D rendered images of skulls. Category 1/mild mice included animals genotypically 
identified as mutants, but phenotypically resembled control mice (no obvious craniofacial 
abnormalities). Category 2/medium mutants had shorter and triangular snouts and wide-
set eyes. Category 3/severe mutants had large areas of undermineralized bones, and were 
excluded from analysis. Images of skulls are not on same scale.  
 
 
 
 
Category 1: mild 
Category 2: medium 
Category 3: severe 
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Figure 5.3: Body weights  (A) Mutants pooled across categories 1 and 2 (MT) treated 
with PBS/peptide had lower body weights than their corresponding controls (CT). No 
differences were detected between mutants in mild or severe categories (B - C). * p < 
0.05 Mann-Whitney Rank Sum test). Sample sizes: n = 10 for CT-PBS and CT-Peptide; n 
= 17 for MT-PBS; n = 18 for MT-Peptide.  
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Figure 5.4: Histological assessment of anterior-frontal (AF) suture fusion. AF sutures 
remained patent in Category 1 mutants (A, B) and in controls (E, F), indicated by black 
arrows. Category 2 mutant mice had fused AF sutures (C, D). Scale bar 200µm.  
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Figure 5.5: Digital caliper measurements of nasal (N), frontal (F) and parietal (P) bone 
lengths and skull widths at the eye and lambdoid sutures. (A) Length ratios were 
calculated relative to the parietal bone, and were significantly higher in controls (CT) 
compared to mutants (MT) irrespective of treatment. (B) MT-PBS mice had significantly 
wider skulls at the eye-level compared to CT-PBS and MT-Peptide mice. * p < 0.05; ** p 
< 0.001. t – tests/Mann Whitney Rank Sum tests were used for N/P and Eye 
measurements, Student Newman Keuls (after two way ANOVA) post multiple 
comparisons for all other measurements. Sample sizes: n = 10 for CT-PBS and CT-
Peptide; n = 14 for MT-PBS; n = 16 for MT-Peptide.  
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Figure 5.6: Digital caliper measurements of categorized mutant nasal (N), frontal (F) and 
parietal (P) bone lengths and skull widths at the eye and lambdoid sutures. Length ratios 
were calculated relative to the parietal bone. (A) Category 1: mild – trends of higher N/P 
and lower F/P and N+F/P length ratios, and (B) lowered widths were measured following 
peptide treatment; (C) Category 2: medium – trends of higher length ratios were 
measured following peptide treatment; (D) Width at the eye-level was significantly 
lowered with peptide treatment; (E) and (F) No effect of treatment on control mice. * p < 
0.05, t - test. Sample sizes: Category 1 PBS n = 4, peptide n = 6; Category 2 PBS and 
peptide n = 10; controls PBS and peptide n = 10. 
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Figure 5.7: µCT measurements of bone volume (BV) and tissue mineral density (TMD) 
around the anterior-frontal (AF) suture in pooled mutants (MT). (A) MT had significantly 
lowered BV than controls (CT) within each treatment. Peptide treated MT had 
significantly lowered BV than PBS treated MT (t – test /Mann Whitney Rank Sum tests). 
(B) Within PBS treatment, MT had significantly lowered TMD than CT. Peptide treated 
CT had significantly lowered TMD than PBS treated CT (Student Newman Keuls post 
hoc comparisons after two way ANOVA). * p < 0.05, ** p < 0.001. Sample sizes MT-
PBS n = 17, MT-Peptide n = 16; CT-PBS and CT-Peptide n = 10.  
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Figure 5.8: µCT measurements of bone volume (BV) and tissue mineral density (TMD) 
around the anterior-frontal (AF) suture in categorized mutants. Category 1 (mild) mutants 
had trends of (A) lowered BV and (B) lowered TMD with peptide treatment. Category 2 
(medium) mutants had significantly lowered BV and trends of higher TMD with peptide 
treatment; * p < 0.05 t-test. Sample size: Category 1: MT-PBS n = 4, MT-Peptide n = 5; 
Category 2: MT-PBS n = 13, MT-Pep n = 11. 
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Figure 5.9: Pre-osteoblasts isolated from mutant mice were cultured in growth medium 
(GM), osteogenic medium (OM) or osteogenic medium supplemented with 300µm of 
pVTK peptide (Pep) for 20 days. von Kossa staining showed that peptide treatment did 
not inhibit mineralization in these cells.  
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 Chapter 6 
Summary and Future Work 
 
6.1 Effect of peptide phosphorylation on apatite binding and mineralization 
In Chapter 2, phosphorylation and amino acid sequence were used as tools to control both 
peptide-mediated binding to synthetic and biological apatite, and inhibition of 
mineralization in vitro. Phosphorylation resulted in increased pVTK binding and 
specificity to carbonated forms of synthetic apatite, compared to non-phosphorylated 
peptide. Altering amino acid order and charge distribution had no effect on 
phosphopeptide binding to synthetic apatite. Hence, phosphorylation provides a 
significant benefit in tailoring and refining peptide binding to biomaterials, and this 
advantage of increased affinity and specificity overrides any effects of altered charge 
distribution and sequence.  
When applied in vitro to osteoblast cultures, pVTK dose-dependently inhibited 
mineralization, whereas non-phosphorylated peptide had no effect on mineralization. 
Altering amino acid order and charge distribution reduced pVTK’s ability to inhibit 
mineralization, but had no effect on peptide binding to cell-secreted mineral. Therefore, 
phosphorylation of VTK is required to inhibit mineralization. Additionally, peptide 
sequence and charge distribution play different roles in pVTK binding to mineral vs. 
inhibition of mineralization – peptide composition and overall charge were more 
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 important in binding to apatite, while amino acid sequence and peptide charge 
distribution were more important in inhibiting mineralization.  
The use of phosphorylation as a means to modulate protein properties is relevant in a 
broad range of biomaterial and tissue engineering applications. The number and relative 
spacing of phosphorylated residues can be optimized to modulate protein binding, 
specificity and affinity to any substrate, allowing easy engineering of surface properties. 
Modification of material surface characteristics will in turn provide control over 
recruitment and interactions with specific biomolecules and/or cells in vitro and in vivo. 
Further, the role of phosphorylation in inhibiting bone can be exploited to create smart 
biomaterials with patterned peptides at different concentrations, which will be able to 
inhibit calcification in a gradient manner. These materials can then be used to spatially 
control and restrict bone regeneration within desired regions and prevent calcification of 
adjoining cartilage/soft tissue. 
 
6.2 Mechanisms of mineralization inhibition in vitro 
In Chapters 3 and 5, we advanced our understanding of the mechanisms of pVTK-
mediated inhibition of mineralization. The effects of peptide on key regulators of 
osteoblast mineralization were studied. pVTK was internalized by MC3T3s within one 
hour of incubation, but had maximal effects on gene and protein expression only at day 
10 following induction of osteoblast differentiation and later, when mineralization 
usually begins. Peptide treatment caused MC3T3 cells to upregulate the expression of 
positive regulators of mineralization such as bone sialoprotein (BSP), Runx2 and tissue 
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 non-specific alkaline phosphatase (TNAP), and downregulate the negative regulators 
such as ectonucleotide pyrophosphatase phosphodiesterase 1 (Enpp1), ankylosis protein 
(Ank) and osteopontin (OPN). Additionally, phosphopeptide bound strongly to both 
synthetic and cell-secreted apatite (Chapter 2). Hence it was hypothesized that pVTK 
binds to initially formed mineral nuclei and prevents their growth, and the cells alter their 
expression profile to a pro-mineralization state in an attempt to compensate and 
overcome the lack of mineralization. However, pVTK treatment in primary pre-
osteoblasts with enhanced BMP signaling did not inhibit mineralization (Chapter 5), 
implying that peptide-mediated physico-chemical prevention of mineral crystal growth is 
not the primary mechanism underlying mineral inhibition. Altered extracellular and 
intracellular concentrations of inorganic phosphate (Pi) or pyrophosphate (PPi) with 
peptide treatment may be contributing to mineral inhibition and should be analyzed 
(discussed in Future Work). Finally, it was demonstrated that peptide cytotoxicity, 
calcium chelation or negative effects of peptide on cellular collagen matrix production 
were not mechanisms of mineral inhibition. 
Understanding the mechanisms underlying peptide-mediated inhibition of mineralization 
will allow the development of a novel class of peptide drugs designed to treat undesired 
calcification, which is associated with a large number of clinical conditions (including 
but not limited to cardiovascular disease, craniosynostosis, osteoarthritis, chronic kidney 
disease, diabetes, kidney stones and dental plaque). Furthermore, calcification of 
bioprosthetic heart valves is a leading cause of valve failure and can also be potentially 
prevented using mineral inhibitory drugs. In addition to its effects on cell differentiation, 
pVTK was also able to completely prevent the progression of mineralization once it had 
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 started. This finding is advantageous in the development of pVTK as a drug, as it fulfils 
the key requirement of a therapeutic to be able to stop further disease progression before 
pursuing subsequent clinical strategies for disease management. Peptide treatments can 
also be potentially supplemented with simultaneous delivery of growth factors or other 
biologics promoting the regeneration of healthy tissue.   
 
6.3 Animal model characterization and in vivo delivery of peptide 
Several animal models of pathological calcification were evaluated as potential 
candidates to test peptide efficacy in vivo (Chapter 4). Phenotype and severity of 
pathological calcification was dependent on mouse genetic background. Enpp1 knockouts 
bred on a pure C57BL6 background did not develop robust vascular calcification when 
compared to knockouts maintained on a mixed background. Crouzon mice with FGF2R 
mutations developed more severe craniosynostosis when bred on a C57BL6 background 
vs. a BALB/c background. Hence, it is important to characterize the contributions of 
genetic factors on occurrence and severity of pathological calcification disorders. 
In Chapter 5, pVTK was locally delivered to prematurely mineralizing anterior-frontal 
(AF) sutures in a mouse model of bone morphogenetic protein (BMP)-mediated 
craniosynostosis. Large variability in phenotype severity was observed, possibly due to 
mice being maintained on a mixed genetic background, or due to differences in Cre 
recombinase expression. To reduce the variation observed, mutants were separated into 
mild, medium and severe categories based on severity. Peptide treatment partially 
corrected craniofacial morphologies in medium category mutants, but did not prevent 
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 suture fusion, indicating the need for higher/longer dosing of peptide, or differences in 
mechanisms involved in suture fusion vs. morphological abnormalities. pVTK also 
lowered bone volume (BV) in mutants and lowered tissue mineral density (TMD) in 
controls, suggesting potentially negative effects on bone growth and/or turnover. 
Characterization of peptide efficacy and demonstration of inhibition of pathological 
calcification in vivo are key steps in the drug development process. With this information, 
suitable drug delivery vehicles can be developed and tested to tailor peptide release based 
on the specific disease etiology and progression for different types of pathological 
calcification conditions. 
 
6.4 Future work 
The work in this thesis describes the characterization and understanding of the newly 
discovered VTK and pVTK peptides. The knowledge gained from this body of work on 
designing phosphopeptide therapeutics, evaluating mechanisms of action and 
characterizing animal disease models can be utilized to derive the next generation of anti-
calcification drugs. Future studies should continue to dig deeper into the mechanisms of 
peptide-mediated inhibition of mineralization, which will in turn provide valuable insight 
into the types of pathological calcification disorders that can be potentially treated with 
pVTK. 
Based on findings of pVTK inhibiting mineralization, our studies focused on molecules 
that have vital roles in osteoblast mineralization. Peptide treatment significantly altered 
Enpp1, Ank, Pit-1 and TNAP expression, all of which are directly involved in Pi and/or 
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 PPi regulation. Direct quantification of any changes in Pi and PPi levels with peptide 
treatment, will provide a better understanding of how lowered Enpp1, Ank, Pit-1 and 
increased TNAP expression levels are contributing to mineral inhibition. In addition to 
their roles as Pi and PPi regulators at the osteoblast membrane, TNAP and Enpp1 also 
have ATPase, ADPase and pyrophosphatase activities in matrix vesicles (membranous 
structures where mineralization is thought to be initiated), which can contribute to 
changes in localized Pi and PPi concentrations [1,2]. Analysis of Enpp1, TNAP and 
Pi/PPi levels in matrix vesicles derived from pVTK-treated matrix vesicles would 
provide further clarity in understanding the effect of peptide on the initiation of 
mineralization. 
Incubation of MC3T3 cells with fluorescently labeled pVTK showed peptide uptake and 
internalization within 1 hour, with fluorescent signal observed in association with 
cytoskeletal structures as well as in perinuclear intracellular compartments. Identification 
of the specific vesicular structures involved in peptide internalization will help 
understand cellular processing of pVTK and subsequent downstream gene expression 
changes observed with peptide treatment. Additionally, it is important to determine if 
pVTK enters the nucleus of treated cells before use in any therapeutic applications. 
Altering charge distribution and phosphorylated amino acid spacing by scrambling 
peptide sequence lowered pVTK’s ability to inhibit mineralization. Changes in amino 
acid order could be affecting the conformation and secondary structure of the peptide, 
and altering the way it is presented to the cells and should be characterized. Repeating the 
mechanistic studies described in this thesis with the scrambled phosphopeptide, will 
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 elucidate the effects of charge distribution on cellular uptake, differentiation and 
mineralization, when compared to non-scrambled pVTK. 
pVTK failed to inhibit mineralization of primary mutant osteoblasts derived from mice 
with enhanced BMP signaling, opening up new avenues to explore in elucidating 
mechanisms of inhibition. Mutant osteoblasts had upregulated BMP and FGF signaling 
pathways (increased phosphorylated Smad and ERK levels), but no changes in 
proliferation, TNAP activity or mineralization were observed [3]. Studying the 
expression levels of other regulators of mineralization such as Enpp1, Ank, OPN, BSP 
and Runx2 will help understand their interactions with BMP and FGF signaling, both in 
the absence and presence of pVTK. Additionally, testing the ability of pVTK to inhibit 
mineralization in a variety of normal and genetically modified osteoblasts will help 
narrow down potential mechanisms to explore, as well as determine what genetic mouse 
models are appropriate to demonstrate inhibition of pathological calcification in vivo.  
pVTK delivery to the AF suture in a BMP-mediated mouse model of craniosynostosis 
resulted in a correction of the wide-set eyes observed in mutants, but did not prevent 
suture fusion. When premature suture fusion occurs in craniosynostosis patients, bone 
growth is unable to proceed normally in the affected areas, while the remaining skull 
bones continue to grow parallel to the fused sutures, resulting in abnormal skull shape 
and eye placement. Our observations of normal eye width, as well as trends of increased 
bone length ratios despite suture fusion in peptide-treated mutants, suggest potentially 
different mechanisms contributing to suture fusion vs. craniofacial abnormalities in this 
model of craniosynostosis. Further investigation into craniofacial morphological changes 
vs. suture fusion will help advance our understanding of craniosynostosis, and possibly 
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 aid the development of new treatments. Alternatively, the use of higher peptide dosage or 
longer treatment times than the parameters used in our studies, may prevent premature 
suture fusion.  
Peptide treatment resulted in lowered BV in mutants and lowered TMD in control mice. 
Histomorphometric measurements of bone growth and turnover using calcein or Alizarin 
red fluorochrome injections can identify the reasons for lowered BV and TMD in 
peptide-treated mice.  
As an intermediate step before further testing pVTK in genetically modified animal 
models of pathological calcification, the effect of peptide on bone regeneration or healing 
defects in wild type mice can also be tested. For example, the healing of non-critical 
sized defects created in mouse calvaria can be studied with or without peptide treatment. 
Similarly, the ability of pVTK to prevent bone formation in ectopically implanted 
osteoconductive biomaterials can also be tested. However, in using wound healing 
models, the presence of inflammatory cells and cytokines may affect peptide properties 
or stability. Development and characterization of delivery vehicles to provide gradual and 
sustained release of peptide over the time period of bone formation will be beneficial. It 
is also important to characterize the stability and clearance rates of the peptide in vitro 
and in vivo, to tailor dosage and release characteristics from delivery vehicles. 
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